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ABSTRACT 
 
DESIGN, SYNTHESIS AND EVALUATION OF DIPHENYLAMINES AS MEK5 
INHIBITORS 
 
 
 
By 
Suravi Chakrabarty 
December 2014 
 
Dissertation supervised by Dr. Patrick T. Flaherty 
 The mitogen-activated protein kinases (MAPK) are a family of interrelated signal 
transduction kinases mediating intracellular responses to extracellular events.  They are 
involved in mediating complex cellular events including, cell differentiation, cell 
proliferation, and cell death.  Extracellular mitogens or the binding of other ligands to 
cell-surface receptors begin a signaling cascade that activates MEK resulting in 
phosphorylation of its corresponding and specific and parallel ERK (Extracellular signal-
Regulated Kinase) substrate.  The MEK5/ERK5 pathway is involved in cell survival, 
anti-apoptotic signaling, angiogenesis, and cell motility.  It is significantly up-regulated 
in specific tumor types including breast and prostate cancers.  A novel series of 
compounds utilizing the diphenylamine scaffold was designed and synthesized based on 
a homology model of MEK5 using the X-ray crystal structure of MEK1 (PDB ID: 3EQC) 
 v 
as a template.  The compounds were tested for their MEK12, and MEK5 inhibition in a 
cell based assay. 
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Chapter 1 
 
Biological Literature Review 
 
1.1  Breast Cancer 
Cancer accounted for 8.2 million deaths worldwide in 2012 (the last complete year of 
WHO record) establishing it as one of the leading causes of death.1  Breast cancer ranks 
fifth for all cancer deaths and is the most lethal cancer for women from less developed 
countries.  In more developed societies breast cancer is the second highest cause of 
cancer death (198,000 deaths, 15.4%) after lung cancer.1 
Incidence rates of in situ as well as invasive breast cancer (vide infra) rose rapidly during 
1980s as shown in the demographic (Figure 1).2  Possible explanations for this rise may 
include increased mammography screenings, better diagnosis and an increase in the total 
number of individuals in this demographic group. 
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Figure 1: Incidence Rates of Female Breast Cancer, by Age, US, 1975-2010 
In Situ (a) and Invasive (b).2 
 
Breast cancer (BrCA) is a heterogeneous collection of cancers targeting the breast which 
vary by anatomical origin, protein expression, and cell-cycle phase. Although these 
variations make the disease complex, understanding the details of this variation provides 
multiple opportunities for therapeutic intervention.  While it is reported that there are 
over 2 million breast cancer survivors in the United States, in reality 5-10 % of these 
individuals will experience a relapse within the next 10 years. 
Breast cancer is multifactorial and results from a complex -yet poorly understood- 
interplay between environment and genetics.  This is consistent with the “two-hit” or soil 
and seed hypothesis for cancer originally proposed by Knudon in 1971.3  Subsequent 
models have been proposed, but most retain this complex inter-play of both 
environmental and genetic contributions.4  Environmental factors increasing the 
development of breast cancer include alcohol use, obesity, and physical inactivity.  These 
factors contribute to 21% of all breast cancer deaths worldwide.5 Prolonged exposure to 
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endogenous estrogens, arising from an early menarche, late menopause, and a late age for 
first childbirth are also significant risk factors for breast cancer. Though controversial, the 
use of exogenous hormones for oral contraceptive or hormone replacement therapy may 
also present an increased risk for developing breast cancer.6 
Several genetic risk factors for breast cancer have previously been identified, and many 
are well-documented (Table 1).  These include BRCA1 (chromosome 17q), BRCA2 
(chromosome 13q12), BRCATA (chromosome 11q), BRCA3 (chromosome 13q21), 
BWSCR1A (chromosome 11p15.5), TP53 (chromosome 17p), and  RB1CC1 
(chromosome 8q11).7   BRCA1, BRCA2 and p53 mutations can result in a very high risk 
for breast cancer and are the most extensively studied. 
Race White 
Age >50 
Genetics BRCA1 or BRCA2 mutation 
Previous medical history Endometrial cancer 
Proliferative forms of fibrocystic disease 
Cancer in other breast 
Menstrual history Early menarche (under age 12) 
Late menopause (after age 50) 
Reproductive history Nulliparous or late first pregnancy 
 
Table 1:  Factors associated with increased risk of breast cancer.6b 
The recognition that a significant amount of the genetic risk is understood, yet not 
quantitatively predictive has focused an increased attention to early adaptive changes in 
 4 
pre-cancerous and cancerous lesions. Presumably this would represent an adaptive 
change to the initial event and the genetic predisposition would represent the ability for 
this event to precipitate cancer. Also, this refocusing on early events is the result of 
earlier identification of breast cancers due to increased screenings. The challenge now 
becomes to treat breast cancer in its earlier stages.  These early stages are phenotypically 
different than the later stages of breast cancer.  Of particular note is that the proto-
oncogenes, the phorbol esters, activate the MAPK cascade, specifically the MEK5/ERK5 
cascade.  Members of this cascade are dramatically up-regulated in early and aggressive 
breast cancer.8  Thus there is a need for the development of new therapeutic approaches 
that can treat breast cancer identified in its early stages. 
There are currently 53 drugs approved by the US Food and Drug Administration for the 
treatment of breast cancer.  Amongst these, chemotherapeutic drugs such as DNA 
alkylating agents (e.g. Cyclophosphamide in combination with Doxorubicin), 
antimetabolites (e.g. Methotrexate), microtubule targeted antimitotic agents (e.g. 
Paclitaxel), antineoplastic antibiotics (e.g. Doxorubicin) and SERMs (selective estrogen 
receptor modulators) (e.g. Tamoxifen and Toremifene) are most commonly employed. 
Other newer, but less commonly used agents target the EGFR/ERRB2 or ESR1 pathways 
(e.g. Erlotinib). The current recommendation9 of profiling of cancer phenotype and 
genotype provides the opportunity to better characterize the specific nature of the cancer 
from each individual.  The development of new drugs that specifically target the adaptive 
change10 unique to each cancer phenotype/genotype is a current and active goal of drug 
development. 
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1.1.1 Categories of Breast Cancer 
Breast cancer is categorized on the basis of tissue origin and phenotype of the cancer. 
Overtime, this phenotypic expression of proteins may change; noninvasive 
(nonmetastatic or cancer that has not spread outside of its tissue of origin) BrCAs may 
develop into malignant or invasive cancers through a series of changes that increase the 
rate of cancer growth, replication, and invasiveness.  Ductal carcinoma in situ (DCIS) and 
lobular carcinoma in situ (LCIS or Lobular Neoplasia) are presented diagrammatically in 
Figure. 2 and 3.  DCIS begins in the epithelial lining of the breast ducts.  LCIS begins in 
the milk-producing lobules of the breast tissue.  Both of these cancers are classified as 
“in-situ” because they are -at the time of characterization- localized and not invading 
past the basement membranes into other breast tissue structure. 
 
Figure 2:  DCIS: Non-invasive abnormal cells found in the epithelial lining of the milk 
ducts.11  
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Figure 3:  LCIS: Non-invasive abnormal cells found in the lobules of the breast.11 
 
Either of these cancers can become more aggressive and invasive due to changes in 
protein expression resulting in metastatic breast cancer.  Due to the changing character of 
these cancers -regardless of tissue origin- it has been found useful to further categorize 
breast cancer types based on hormone receptor expression.  The receptors most 
commonly altered in breast cancer are ER (Estrogen Receptor), PR (Progesterone 
Receptor) and HER2 (Human Epidermal Growth factor receptor-2). 
 
1.1.1.1  Estrogen Receptor+ 
75% of BrCAs are Estrogen Receptor + (ER+) and express ER on the cell surface.  These 
receptors are normally inactive and can be activated by the presence of endogenous 
steroids or synthetic steroid agonists.  Conversely, they can be inactivated by the 
presence of steroid antagonists.  These receptors are internalized following agonist 
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binding, relocate to the nucleus, and initiate gene transcription.  These receptors can also 
be internalized without steroid binding, in which case they normally do not result in gene 
activation.   Amongst these ER+ cells, 65% are also Progesterone Receptor+ (PR+).  
Estrogen-receptor positive breast cancers are further categorized into luminal A and 
luminal B subtypes. Luminal A breast cancers have the highest levels of estrogen 
receptor expression and tend to be low-grade and less invasive cancer. Luminal B breast 
cancers are ER+ (and either PR+ or PR-) and HER2+.  The designation of a negative 
receptor profile indicates that the cell does not express the receptor on the cell surface 
and consequently the ligand cannot bind and subsequently induce gene expression.  
These cancer cells, however, may activate the expression of agonist-dependent genes 
regardless of receptor occupancy.  In such a case, these receptor negative cell types are 
designated constitutively active and receptor negative cells. 
 
1.1.1.2  Her2 type12 
The second class of relevant breast cancer receptors are designated as Her2 for Human 
Epidermal Growth factor receptor-2 type.  These breast cancer cells express Her2 
receptors which upon activation express Her2-related genes. Breast cancer cells can be 
either ER+ or ER– and independently can also be PR+ or PR-.  Approximately 20-30% 
of all breast cancers over-express Her2; as a result Her2 designations have been clinically 
determined routinely since 2007 and serve as a prognostic indicator of the disease.  Her2 
does not become activated upon ligand binding and is therefore classified as an orphan 
receptor.  Activation of Her2 requires either ligand-dependent heterodimerization with 
EGFR (Epidermal Growth Factor Receptor) or a different membrane receptor.  
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Alternatively, ligand-independent homodimerization can also generate an active 
complex.12  Activation of Her2 receptors is an early event in breast tumorogenesis and its 
unique expression in human breast tumors has established this receptor as a clinically 
validated therapeutic target. 
 
1.1.1.3  TNBCs 
The third major breast cancer subtype defined by receptor expression is designated 
“basal-like” and shares significant overlap with the triple-negative class of breast tumors 
(TNBC) (Figure 4).13  Both basal-like and TNCB cancers are characterized by a lack of 
all three characteristic breast-cancer receptors: ER, PR, and HER2. These triple-negative/ 
TNBC cancers display aggressive growth, invasiveness, and are associated with 
characteristic histologic features.  These histological features include: solid-pushing 
borders, geographic areas of necrosis, and regions with dense lymphocytic infiltration. 
TNBCs constitute 10-25% of the breast cancers commonly presented in patient 
populations, and are the most aggressive histological subtype with respect to both 
morbidity and mortality.14 
 
Figure 4 A, B: Extensive overlap of expressed genes between the basal and TN subtypes. 
A set of 50 genes (Pam50 or Prediction Analysis of Microarray 50) was developed for 
classifying subtypes of breast cancer.13-14 
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TNBCs are a diverse and heterogeneous group of tumors that -by definition- lack 
estrogen receptors, progesterone receptors and do not show over-expression of HER2 
receptors.  The majority of the tumors classified as TNBCs are highly malignant and only 
a subgroup of TNBCs respond to conventional chemotherapy resulting in a less than 
favorable prognosis in most cases.  Results from decades of research have identified 
important molecular characteristics that can subdivide this group of breast cancers 
further.  High-throughput cellular profiling techniques including sequencing, pathway 
analyses, and integrated analyses of alterations at the genomic level the gene transcription 
level have improved understanding of how bimolecular alteration results in tumor 
development and progression.  The current challenge is to exploit this knowledge to 
develop new therapeutic agents.15 
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Table 2 below delineates the subtypes of breast cancer and their histology. 
 
Molecular 
Subtype 
ER+ Her2 Basal 
Luminal A Luminal B 
Genetic profile Amplified ER related genes 
(A>B) 
Amplified Her2 
related gene on 
chromosome 
17q 
ER-/ PR-/ 
Her2 - 
Increased Basal 
CKs 
Histologic 
correlates  
 
Lower-grade 
ER+ 
 
Higher-grade 
ER+ 
 
High-grade, 
+/– apocrine 
features 
 
High-grade, 
sheet-like, 
necrosis, 
inflammation 
 
Prognosis 
 
Good 
 
Worse than 
luminal A 
 
Poor 
 
Worse 
 
Response to 
Chemotherapy 
Less 
responsive; 
most likely to 
respond to 
endocrine 
therapy 
 
Intermediate 
 
Higher 
 
Higher 
 
Targeted 
therapies 
 
Hormone therapies 
HER2-targeted 
therapies 
Currently 
investigational 
 
 
Table 2: The characteristics of the basic molecular/intrinsic breast cancer subtypes.16 
 
The luminal subtypes A & B share expression of estrogen receptor (ER)–related genes 
and have better overall survival than the HER2-related and the basal-like subtypes, which 
are typically ER negative.  To establish the prognosis of the disease, tumor grade and 
factors such as, the stage of cancer, patient’s age and general health is determined.  A 
lower grade cancer is well differentiated and indicates a better prognosis, whereas, a 
higher grade cancer is poorly differentiated and may grow and be invasive more quickly. 
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Thus, a more aggressive treatment may be required for higher grade breast cancer 
subtypes.  Targeted therapies are available for patients with ER-positive and HER2-
positive tumors, while those with TNBC are left without the option for the above 
therapies. 
 
1.2  Epithelial to Mesenchymal transition/ Mesenchymal to epithelial 
transition 
This invasive property of breast cancers was recognized over 120 years ago by Ram´on y 
Cajal who described the process of how breast ductal epithelial cells developed a 
different cellular morphology and also developed the ability to migrate into the stroma to 
become an invasive cell type.  EMT has been described as a process of cell phenotype 
alteration where epithelial cells are altered to a cell phenotype more representative of a 
mesenchymal type.  Epithelial cells are attached to the basement membrane and are 
polarized.  They are tethered together as a flat 2-dimensional matrix through E-cadherin 
and other protein strands.  Mesenchymal cells, on the other hand, have decreased E-
cadherin and are less strongly tethered to adjacent cells.  Other cadherins such as N-
cadherin and cadherin 11 are significantly up-regulated.  It has been shown that breast 
cancers that lack expression of E-cadherin show increased tumorigenesis and metastatic 
potential.17  Therefore, it has been proposed that EMT is a key transitional program 
invoked during cancer invasion, metastasis, and development to chemotherapeutic 
resistance.18  It was subsequently recognized that pro-oncogenic transcription factors 
could produce this EMT change of phenotype.19  The most commonly associated pro-
oncogenic transcription factors are Snail, Twist and Zeb. Snail is an oncogene that is 
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activated by FGF, Wnt, and TGF Activation of Snail directly suppresses the epithelial 
phenotype by repression of E-cadherin expression.  Additionally Snail promotes cellular 
motility. Both Snail1 and Snail2 are potent inducers of EMT20 and are highly expressed 
in breast, GI tract, ovarian, and pancreatic tissue.21  The amount of Twist1 activation, the 
loss of E-cadherin, and the increase of vimentin are all correlated with increased tumor 
cell motility, metastasis, tumor cell presence in the blood, and development of new 
remote lung tumors.22  ZEB proteins are zinc finger E-box binding homeobox1 
transcription factors.  Elevation of ZEB1 levels inhibit expression of the T-lymphocyte-
specific IL2 gene.  ZEB1 also represses the E-cadherin promoter indirectly and induces 
EMT in the presence of SMARCA4/BRG1.23  It has been found that activation of MAPK 
cascades cause an up regulation of Snail, Twist, and Zeb genes24 and thus activation of 
these pathways may represent early pro-oncogenic events. 
 
Figure 5: External contributions to EMT.24 
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Figure 6: EMT/MET.24 
 
1.3  Protein kinases as drug targets: 
Protein kinases catalyze many of the most vital physiological and biochemical processes 
in the human body.25  Protein kinases can directly phosphorylate proteins, typically at 
Ser, Thr, or Tyr residues.   This biochemical event alters the local and net charge of the 
protein.  This alteration can result in the acquisition of new chemical, biological, and 
physical properties for the substrate protein.  These kinase-mediated phosphorylation 
events can change the shape of proteins, modify biochemical activity, alter protein-
protein interactions, and alter sub-cellular localization.  There are in excess of 510 known 
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human kinases.  Of these, about 90 % of the known kinases, or kinome, phosphorylate 
Ser, Thr, or Tyr and are known as “Typical” kinases.   The biochemical mechanism of 
these typical kinases are increasingly well understood.25  As a group of related structures, 
these typical kinases often display the ability to exist in either an active or inactive form 
(often based on their own post-transnationally modified state) and bind ATP and Mg++ 
ions in well-conserved manner.  This allows them to have significant homology in the 
ATP binding domain, whereas significant differences in the substrate-binding domains, 
and to have a carefully conserved enzymatic mechanism for both substrate binding and 
product release.  The remaining 10 % of the kinases in the human kinome are structurally 
very different than the typical kinases and display less homology, and significant 
differences in their activation strategy and proposed enzymatic mechanism.  These 
atypical, or “pseudo-kinases” are often compartmentalized into sub-cellular regions with 
other typical kinases and are proposed to mediate cell-signal transduction, scaffold 
proteins, or modify gene transcription.25 
Due to the large number of different kinases and their important biological roles, many 
kinases have been utilized as therapeutic targets for drug action.  A list of kinase 
inhibitors approved in 2013 are listed in Table 3.  The involvement of kinases in the 
regulation of basic cellular functions including proliferation, growth, differentiation, and 
apoptosis has resulted in several kinases as being important therapeutic targets for the 
treatment of cancer.  Although at the current time there are more than 510 known human 
kinases, only 50 kinases have been the focus of significant medicinal chemistry and drug-
design efforts.26  The therapeutic category for most, but not all, of these kinases is cancer. 
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Drug Structure Inhibitor 
type 
Known 
target 
Indication 
Afatinib27 
(Gilotrif) 
 
Irreversible 
Type I 
EGFR NSCLC 
Dabrafenib28 
(Tafinlar) 
 
Reversible 
Type I 
B-RAF Melanoma 
Ibrutinib29 
(Imbruvica) 
 
Irreversible 
Michael 
acceptor 
Bruton’s 
kinase 
Mantle cell 
lymphoma 
and CLL 
Trametinib30 
(Mekinist) 
 
Type III MEK 1/2 Melanoma 
 
Table 3: Kinase inhibitors approved by FDA in 2013. 
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The biomechanical events for typical kinases are increasingly well understood.  Ser/Thr- 
as well as Tyr- protein kinases share a catalytic domain of  ̴ 290 residues in which the 
active site is sandwiched between an N-terminal lobe composed of a β-sheet, a single α-
helix (the “C helix”), and a larger C-terminal lobe, connected by a linker or “hinge” 
region.  The C-terminal lobe is comprised predominantly of α-helices and includes an 
activation segment, a region of 20–35 residues located near a highly conserved DFG 
motif (this abbreviation is the single letter amino acid codes for Asp, Phe, and Gly), and 
an APE motif, which is less conserved.31  In its active conformation, the C helix packs 
against the N-terminal lobe, and the Asp of the DFG motif chelates a Mg++ ion that 
coordinates with the phosphoryl oxygen atoms of ATP and helps coordinate the 
nucleotide’s geometry and electronics to facilitate transfer of the terminal -phosphate.  
Kinases then phosphorylate the hydroxyl group of Ser, Thr, or the Tyr residues on their 
protein substrates using the γ-phosphate group of ATP carefully positioned in the ATP 
binding site of the kinase (Figure 7). 
 
Figure 7: Schematic diagram of protein kinase catalytic mechanism in case of PKA 
(Protein kinase A).25 
 
In the inactive conformation of typical kinases, the DFG motif exists in a different 
conformation where the Phe of the DFG motif is turned in toward the ATP site25 and the 
 17 
Asp is directed away from the ATP site. This is referred to as the inactive ‘DFG out’ 
conformation indicating the relative location of the Asp residue of the DFG motif.  
Conversely, the active form of the kinase where the Asp is directed toward the ATP site 
(to assist with the binding of ATP and Mg++ ions) is referred to as the “DFG” in 
conformation (Figure 8). 
 
Figure 8: Active catalytic site of PKA with ATP and substrate. PDB ID: 1ATP.25 The 
structure represents a ‘DFG in’ conformation.25 
 
1.3.1  Kinase catalysis and inhibitors 
As knowledge of kinases has increased, largely from X-ray crystal structures (there are in 
excess of 170 protein kinase structures deposited in the PDB) and enzyme kinetic studies, 
it has been recognized that there are multiple ways to inhibit a kinase.  These different 
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ways to inhibit a kinase have been categorized by the geometry of the inhibitor binding 
on the enzyme surface. 
 
Type I inhibitors: The initial kinase inhibitors were designed as ATP-site inhibitors. The 
small molecule competed with the endogenous ligands, ATP and Mg++, for the ATP 
binding site.  These reversible competitive inhibitors bound the catalytic domain with the 
DFG motif oriented with a “DFG-in” conformation.  These type I inhibitors competed 
with ATP for the active form of the protein kinase.  The chemical structure of these 
inhibitor molecules mimic ATP and form hydrogen bonds with the hinge region at the 
catalytic domain (Figure 9). 
 
Figure 9 a, b: Design strategy of Type I inhibitors mimicking select ATP interactions 
 
In recent past, two Type I small molecule inhibitors of the MEK5/ERK5 pathway, 1 
(BIX02188) and 2 (BIX02189) were identified with IC50 values of 4.3 and 1.5 nM, 
respectively.32 
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Figure 10: Examples of Type I inhibitor. 
Achieving kinase isoform selectivity, however, has still remained as a major concern 
because most kinases share a highly conserved ATP-binding site with similar glycine-
rich loop.33  Recently, inhibitor binding sites other than the catalytic -or the ATP site- 
have been exploited for inhibitor design with the goal of improving target selectivity 
based on the observation that regions adjacent to the ATP binding domain vary among 
the different kinases. 
 
Type II kinase inhibitors34 : Type II kinase inhibitors bind to the ATP site after the 
phosphorylation event.  The ATP site is then converted to the ADP release site as the 
DFG motif converts to the “DFG-out” conformation, releasing the side-product molecule 
of ADP and generating the inactive form of the kinase.  This DFG-out conformation 
exposes a new unoccupied hydrophobic pocket (previously occupied by the phenyl side 
chain of the Phe in the DFG motif) permitting new interactions to be explored and 
exploited by small-molecule inhibitors.  This practically results in more potent 
compounds (by a factor of a 20-fold increase in potency) with better selectivity than is 
achievable by targeting the ATP site with the DFG-in conformation.  However, mutations 
can occur at non-essential sites that prevents drug binding (binding the DFG-out 
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conformation), but not the endogenous substrate ATP from binding.  ATP binds the 
DFG-in conformation.  Overall, type II kinase inhibitors may be more prone to the 
development of resistance than type I kinase inhibitors. 
 
Figure 11: Type II inhibitors design with DFG “out” conformation. 
 
Type I ½  kinase inhibitors34:  The type I½ inhibitors bind to the ATP site with the DFG 
motif in the  ‘DFG in’ conformation.  These inhibitors utilize the ATP binding pocket, 
extend past the “gatekeeper” reside at the back cavity of the catalytic domain, and then 
fill a smaller hydrophobic pocket proximal to the “Phe” binding site.  These kinase 
inhibitors have all the features of type I inhibitors and some of the features of type II 
inhibitors.  They are likely to be more potent than just type I inhibitors (typically 5-times 
more potent than structurally similar inhibitors that do not utilize the smaller hydrophobic 
pocket) and selective than type I inhibitors.  However, type I½ inhibitors may still be 
prone to the development of resistance as are type II inhibitors, but perhaps to a lesser 
extent. 
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Figure 12: Designing of a Type I ½ inhibitor. 
 
Type III or allosteric site inhibitors:35  An allosteric site, also known as the Type III 
site, lies adjacent to the ATP-binding domain in many kinases.  This feature, however 
may not be present in all kinases.  Type III kinase inhibitors are small -mostly 
hydrophobic- molecules that do not make any interaction with the hinge region of the 
ATP binding pocket.  These compounds bind in a “side pocket” of the kinase adjacent to 
where the -phsophate of ATP is located.  Binding of these type III inhibitors lead to a 
conformational change in the α-C-helix region and results in a global conformational 
change in the overall enzyme shape.  The conformational change prevents activation of 
the t-loop via phosphorylation.  Theoretically type III kinase inhibitors could be 
stoichiometric (with respect to the enzyme) inhibitors of kinase activity without 
competition for occupancy by endogenous substrates such as ATP or ADP.  The reality 
of this type of kinase inhibition was confirmed by X-ray crystallographic analysis 
approximately 7 years ago and has been confirmed for MEK1,2 for several small 
molecules since.  Despite this, it has only recently been designated as a specific inhibitor 
site and infrequently exploited for medicinal chemistry design strategies.35  
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Figure 13: Type III and Type IV binding pockets with a type III inhibitor (PD-325089) 
bound in the allosteric pocket, adjacent to the ATP pocket; PDB id: 3EQG.35  
 
The practical utility of a type III inhibitor was in question, but the recent FDA approval 
of the MEK1/2 inhibitor Mekinist as an anti-cancer agent confirms the success in using 
this design strategy for drug design.  There is the possibility of development of resistance 
to a type III inhibitor.36  As a result targeting synergistic kinases or appropriate biological 
targets may be necessary to develop a type III inhibitor into successful drug.  
Therapeutically kinases play a very important role in interpreting the 
external/environmental stimuli into the internal cellular responses/signaling and thus can 
be exploited to study the underlying causes of various diseases. Mitogen-activated protein 
kinases cascade are a family of such kinases which have been found to be upregulated in 
breast and prostate cancers and thus holds the key to the better understanding and 
treatment of the disease.   
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1.4  The Mitogen-activated Protein Kinase (MAPK) Cascades 
The mitogen activated protein kinase pathway (MAPK) is a ubiquitous family of 
interrelated, serine/threonine and tyrosine protein kinases which participate in signal-
transduction pathways that mediate important cellular functions. These cascades were 
originally discovered in yeast37, but were subsequently found to be distributed across 
multiple species including humans.  The activation of these pathways can have multiple 
and complex initiation events.  In many cases these pathways are activated by G protein-
linked cell surface receptors including receptor tyrosine kinases and thus are activated by 
signaling molecules such as growth factors, cytokines, neurotransmitters, hormones or 
various cell stressors.  The eventual outcome can be equally diverse including protein 
phosphorylation, activation of transcription factors, post-translational modification of 
cytoskeletal proteins and enzymes.  These outcomes may dramatically modify 
embryogenesis, cell survival, differentiation, proliferation, and cell death. 
These MAPK pathways all involve a sequence of ordered phosphorylation events, in 
which a mitogen-activated kinase kinase kinase (MAPKKK or MEKK) phosphorylates 
the next downstream mitogen-activated kinase kinase (MAPKK or MEK), which 
subsequently phosphorylates the third mitogen-activated kinase (MAPK or ERK). The 
ERKs activate the various downstream transcriptional factors which regulate the 
important cellular processes such as proliferation, gene expression and cell death.  This 
three-tiered kinase cascade is highly conserved across the species.  In humans the most 
extensively studied is the Raf/MEK/ERK pathway due to its relevance to multiple types 
of cancer.38  In Figure 14, a simplified outline of the human three-tiered kinase cascade 
is presented. 
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Figure 14: The MAPK signaling pathway.8 
MAPK cascades may utilize a specific kinase for several different signaling cascades.  
This is true for both yeast and human MAPK cascades.  Although these pathways have 
been extensively studied and are increasingly well characterized in yeast37, there is a 
substantial deficiency in the current understanding of human MAPK cascades.  In yeast 
several strategies have been identified that produce many well-defined cascades with 
seemingly redundant use of specific MAPK enzymes.  These strategies result in very 
little erroneous cross-talk between the pathways.  Some of the yeast MAPK pathway 
strategies identified to date include the use of scaffolding proteins that carefully 
recognize and order the MAPK members correctly, dephosphorylation by phosphatases, 
and conformational changes resulting from kinase oligomerization.  In humans these 
MAPK strategies have also been identified, along with sub-cellular 
compartmentalization, association with structural biomolecules, and possibly other 
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strategies.  In a manner similar to yeast MAPK cascades it has been proposed that these 
strategies when employed in human MAPK cascades may result in well-defined specific 
MAPK pathways with –at first glance- seemingly redundant phosphorylation events.  To 
date it appears that the MEK members of the MAPK kinases are specific for a single 
ERK substrate.  Thus understanding the physiological role of each MEK may assist in 
understanding the pathways that utilize that specific MEK.  The development of small-
molecule inhibitors for each isoform of MEK may assist in understanding the normal and 
pathological roles for each MEK isoform specific pathway. 
 
1.5  MAPK kinase or MEK 
The MEK/ERK1/2 pathway (namely, the Ras–ERK pathway) is the best characterized of 
the MAPK pathways (Figure 15).39 
 
Figure 15: Crystal structure of MEK1 with Mg++ATP in the active site. PDB ID: 3EQC. 
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1.6  MAP kinase 
Of the eight different MAP kinases known to exist within the mammalian cells, 
extracellular signal-regulated kinases (ERK) 1/2, c-Jun NH2-terminal kinases (JNK) 
1/2/3, p38 and ERK5 have been well recognized and studied.  The other ERKs and their 
associated pathways: ERK 3, 4, 7 and 8, still require significant studies.  Activation of the 
ERKs by its respective MEK requires dual-phosphorylation of specific Thr and Tyr 
residues on the substrate ERKs activation loop near the kinase domain within a highly 
conserved T–X–Y motif.  Residue X corresponds to a glutamic acid (Glu; E) for ERKs, 
proline (Pro; P) for JNK and glycine (Gly; G) for p38 subfamilies substrates.  This is 
shown below in Figure 16.  As a result MEKs can be categorized as TY dual-specificity 
kinases.  Note that the sequence presented to both MEK1/2 and MEK5 are identical.  The 
substrate sequence presented to MEK3/6 or MEK 4/7 is TGY and TPY respectively. 
 
Figure 16: ERK1/2, ERK5, p38 MAPKs (α,β,γ,δ) and JNK 1/2/3 are arranged into a 
hierarchical three-tier system known as a MAPK module.40 
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1.7  MEK5 
MEK5 is the MAPK kinase upstream of ERK5.  It is activated by either MEKK2 or 
MEKK3.  MEKK2 has higher binding affinity for MEK5 than MEKK3 although both 
bind the N-terminal of MEK5.8, 41  MEKK2 and MEKK3 phosphorylate MEK5 at both 
Ser311 and Thr315 residues, resulting in the dually phosphorylated pSer-pThr-MEK5, 
the enzymatically active form of MEK5.42  Two splice variants of MEK5 have been 
identified: MEK5-α and MEK5-β (Figure 17).  The difference between the splice 
variants is the length of the variants; MEK5- is 89 amino acids longer than MEK5- in 
N-terminal domain.  Although, specific functional differences between the two splice 
variants has yet to be identified, it has been shown that the ratio of MEK5- to MEK5- 
expression was elevated in cancer cell lines.43  It has been postulated that this structural 
difference may result in a functional difference between the isoforms. 
 
Figure 17: MEK5 splice variants and the pertinent functional domains.43 
MEK5 shares a 48% overall sequence homology with MEK1.8  ERK5 is the only 
substrate of MEK5. This makes MEK5 a unique target for the selective treatment of 
disease states such as cancer. 
 
 
 28 
1.8  ERK5 
ERK5, also known as MAPK7 and BMK1 (big map kinase), was first recognized in 
1995.  MEK5 is the only known upstream MAPKK that can directly activate ERK5. 
Similar to ERK1/2, ERK5 also has a dual phosphorylation site characterized by a TEY 
sequence (Figure 18).  The N-terminus catalytic domain shares 51% identity to ERK1/2. 
ERK5 and is characterized by the presence of a larger C-terminus extension than any 
other ERK enzyme.44  This large C-terminus domain has been proposed as being 
responsible for activation, autophosphorylation, subcellular localization, and nuclear 
shuttling.  ERK5 is an approximately 100 kDa protein and at 816 residues long, hERK5 
is one of the largest of the MAPK family members.44-45  It has been proposed that the 
large size of ERK5 is a functional replacement for the scaffold proteins commonly 
associated with the smaller ERK isoforms.37  The functional domains of ERK5 are shown 
below in Figure 7.  Although platform proteins do not associate with ERK5, other 
proteins do associate with MEK5 and modify its biological function. 
 
Figure 18: Structure and functional domains of ERK5.39 
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1.8.1 ERK5 localization 
The unique C-terminal tail of ERK5 contains a transcriptional activation domain, which 
can either phosphorylate the various transcription factors, or can directly act as a 
transcriptional co-activator.  In the resting state, non-phosphorylated ERK5 folds into a 
“U” shape and the N-terminal domain interacts with the C-terminal domain, to form an 
NES region that has been shown to interact with Hsp90.  In this instance, Hsp90 
behaves as a cytoplasmic anchor protein (Figure 19).  This interaction is responsible for 
keeping resting-state (non-phosphorylated and Hsp90-associated) ERK5 in the cytosol. 
MEK5-mediated phosphorylation of ERK5’s TEY motif results in ERK5 activation, and 
permits ERK5’s additional auto-phosphorylation at its C-terminal which leads to the 
disruption of the intra-molecular interactions.  This induces a conformational change in 
pERK5 that results in dissociation of Hsp90unfolding of ERK5, exposition of the NLS 
region, and subsequent nuclear translocation of pERK5. 
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Figure 19: Mechanism of nucleocytoplasmatic transport of ERK5; TAD: transcriptional-
activation domain.46 
  
1.8.2 ERK5 crystal structure 
The X-ray crystal structure of human ERK5 kinase domain in complex with inhibitor 3 
was recently determined by Knapp et al (Figure 20).47  The structure revealed differences 
in residues in the ATP-binding site, compared to the other ERKs, p38s and JNKs and has 
lead the way for development of selective ERK5 inhibitors. 
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         3 
 
Figure 20: Crystal structure of ERK5 with inhibitor 3. PDB ID: 3H9F.48 
 
1.8.3 Downstream activation of ERK5 
ERK5 regulates a number of downstream transcription factors including the myocyte 
enhancer factor (MEF) family, MEF2A, C, and D.49  ERK5 phosphorylates MEF2C on 
Ser387, which increases MEF2C transcriptional activity resulting in an increase in gene 
expression of c-Jun.  ERK5 is also able to directly enhance the transcription of c-Myc, 
CREB and Sap1a and c-Fos.49b, 50 
 
1.9 MEK5/ERK5 Pathway and Cancer 
The MEK5/ERK5 pathway is a unique signaling pathway triggered by external stimuli 
such as cytokines (LIF, CT-1, IL6), mitogens (EGF, NGF, FGF-2, BDNF), and stress 
including radiation51, palyotoxin52, and phorbol ester treatment52.  The MEK-5 pathway 
allows cells to survive extreme metabolic demands and is significantly up-regulated in 
response to stress.  
During signal transmission, the N-terminus of the activated form of pMEK5 binds to the 
functional domain of its unique substrate ERK5 to convey the activation signal via 
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phosphorylation events described above.  Active pERK5 has two possible cellular 
pathways for signaling; either by activating downstream molecules, such as, Sap1, cFOS, 
c-Myc and MEF2 in the cytosol or by nuclear translocation (described above) and 
transcription activation.53 
 
Figure 21: MEK5/ERK5 pathway.8 
 
1.9.1 Role in tumor development 
Significant effort has been directed toward the development of MEK1/2 inhibitors as 
anticancer agents.  In July 2013, Mekinist, a type III MEK1/2 inhbitor, has been approved 
for cancer therapy.  Due to the development of full inhibition of MEK1 and the partial 
inhibition of MEK2, it is currently recommended that Mekinist be given with a BRAF 
inhibitor.36a  This is the first in class type III MEK inhibitor and it is recommended that 
other MEKs may deserve additional scrutiny.  Over-expression of the MEK5/ERK5 
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pathway has been demonstrated in many cancers.  Most importantly the ERK5/MEK5 
pathways has been shown to be upregulated in breast cancers.10, 54  This upregulation is 
most important in the potential treatment of triple negative breast cancers, which at the 
current time are aggressive and refractory to the majority of present therapeutic 
strategies.14  The up-regulation  in breast cancer occurs early and is correlated with the 
expression of ER  and  gene products in a receptor independent manner.10  This is 
consistent with MEK5/ERK5 as an early mediator of ER(-) breast cancers.10  
Additionally it was found that immunohistochemical staining of excised human breast 
cancer tissue for ERK5 (phospho-form not specified) indicated decreased survival time 
for patients who over-expressed ERK5.54a  Analysis of gene products from these same 
tissues identified that cells overexpressing ERK5 were consistent with excessive 
constitutively active HER2 activity.  Thus MEK5 inhibitors have been10 suggested as 
potentially useful for the treatment of the most dangerous and least successfully treated 
variety of breast cancer. 
The MEK5/ERK5 pathway is also significantly up-regulated in squamous cell carcinoma 
and prostate cancer.  Sticht et al. discovered high levels of ERK5 association, but not 
ERK1 expression, in advanced stage tumors and lymph node metastases from oral 
squamous cell carcinoma (OSCC) patients.55  Mehta et al. not only documented moderate 
expression of MEK5 in 44% of prostate tumors overall, but also identified that in 37% of 
tissues excised from patients, MEK5 was highly expressed.56  In malignant 
mesotheliomas, HGF (Hepatocyte growth factor) has been shown to be highly expressed 
and stimulates proliferation through the PIK3/ERK5/fos-related antigen 1 (fra-1) 
pathway.  Furthermore, ERK5, but not ERK1, was shown to contribute to the Src-
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mediated structural disruption of the actin cytoskeleton. This disruption may be the first 
phase in development of metastatic disease.48, 55  This observation is consistent with 
MEK5/ERK5 representing an early conversion to an invasive cancerous phenotype. 
Taken together, these observations suggest that MEK5/ERK5, as a downstream target of 
EGFR, may be a novel molecular target and potential interference point in future 
therapeutic approaches given its association with advanced tumor stage particularly if 
mutations have occurred upstream at the level of the tyrosine receptor kinases. 
Two commonly used human breast cancer cell lines, BT474 and SKBR3, have been 
shown to express a constitutively active form of ERK5 in activated ErbB2, ErbB3 and 
ErbB4 cells. When these cells were treated to ErbB receptor activity inhibitor, ERK5 was 
found to be inactivated thus indicating the involvement of ERK5 in proliferation of these 
breast cancer cells.57  Thus it is reasonable to speculate that the MEK5/ERK5 cascade 
may be a pro-cancerous phenotypic adaptation. 
After considering the above recent findings regarding MEK5, it is apparent that this MEK 
isoform requires additional study.  The development of new small molecule inhibitors of 
the MEK5/ERK5 signaling pathway could contribute to these studies that examine the 
pathophysiological role of MEK5, particularly in the previously mentioned cancers. 
It may well be that multiple activity MEK inhibitors may be desirable and perhaps useful, 
but at the current time it is unclear how the various MAPK pathways interact.  It is 
known that one MAPK pathway can modify another MAPK pathway.58  Additionally, 
there are more complex biological mechanisms that that can apparently upregulate the 
activity of other MAPK pathways.59 
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1.10  Development of Mekinist as MEK1/2 inhibitor60 
 
 
Figure 22: Compound 4 and analogues.61 
Compound 4 (CI-1040/ PD184352) is a well characterized, highly potent and selective 
Type III inhibitor of MEK1 and MEK2 initially identified in 1999.  It displays significant 
antitumor activity in vivo54b, 62 and was the subject of a multicenter Phase II clinical trial 
in patients with advanced non small-cell lung cancer, breast cancer, colon cancer or 
pancreatic cancer.63  However, the advancement of 4 into clinical trials revealed a 
number of pharmacological problems, including metabolic instability and low overall 
bioavailability.64  Second generation analogs, for example compounds 5, 6 and 7, 
displayed greater potency and improved oral bioavailability.  The crystal structures of 
MEK1 and MEK2 with compounds 6 and 7 respectively (Figure 23), identified that these 
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small molecule inhibitors bind to the novel allosteric (or type III) binding pocket adjacent 
to -but not overlapping with- the Mg++/ATP binding site.65 
 
 
Figure 23 a, b: MEK1 and MEK2 homodimer structures respectively. The nucleotide-
binding loops are blue, the catalytic residues are gold, the activation loops are red, ATP is 
pink and the ligand is orange.66 
 
The key interactions observed between the inhibitors and the adjacent amino acid 
residues of this binding site were (Figure 24):61 
1. Numerous van der Waals interactions of the B ring of the inhibitor with the amino 
acid side chains of the hydrophobic pocket formed by Met143, Ile141, Leu118, 
and Phe209.  Phe209 also formed a critical edge-to-face aromatic interaction with 
the B ring. 
2. A hydrogen bond interaction was shown to exist between the 4-fluoro atom of the 
inhibitor A ring and the backbone amide of Ser212. 
3. The backbone carbonyl oxygen of Val127 formed an electrostatic interaction with 
the 4′-iodide at the back of the pocket.  This interaction is now known as the 
halogen bond.67 
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Figure 24: MEK1/2 interactions with inhibitor 5 (PD325901). 
A halogen bond is a newly identified, short-range electrostatic interaction of a halogen 
atom with a lone electron pair from heteroatoms including O, N and S. The electron 
density from the lone pair of the heteroatom is loaned to the antibonding orbital of the 
halogen (Figure 25).  
 
Figure 25: Schematic of halogen bond. 
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Figure 26: Halogen bond from compound 5 to acyl lone pair of backbone Val127 in 
3EQC.  Bond angle: 127.8 o, Bond distance: 3.11Å 
 
This led to the structure-guided design of a new class of potent inhibitors of MEK1 and 
MEK2, represented by 4-(phenylamino)-5-carboxamido-2-pyridone 8, where, the 
difluorophenyl group from the diphenylamine class was replaced with the pyridine in 
order to ascertain the improvement of the hydrogen bond interaction with Ser212.  SAR 
studies were conducted to optimize the R1, R2, and Ar on a variety of relevant parameters. 
 
1. Optimization of the Carboxamide Side Chain61 
From the second generation diphenylamines (5 and 6), it was expected that 
introduction of a carboxamide would both increase the potency and improve the 
pharmacokinetic properties relative to the acid.  The simple carboxamide 9 (table 4) 
on the series 4-(phenylamino)-5-carboxamido-2-pyridone was highly potent against 
the Raf-MEK-ERK cascade and was significantly active in the colon26 cellular assay. 
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The colon26 cellular assay utilizes murine colon adenocarcinomas originally isolated 
from mouse lung that are stable yet metastatic after 26 passages.  It is used as a model 
for aggressive metastatic cancer.68  This cell line is convenient to maintain sensitive 
to MEK1 inhibitors and is a standard in vitro test for cellular efficacy of MEK 
inhibitors against malignant tumors.69  The mono- or dimethylation of the amide 
nitrogen greatly diminished this potency. 
 
Compound R1 Cascade 
IC50(µM) 
Cellular 
IC50(µM) 
9 NH2 0.023 0.004 
10 CH3NH 0.195 -- 
11 (CH3)2NH 0.627 -- 
12 HOCH2CH2ONH 0.018 0.005 
 
Table 4: Optimization of the Carboxamide Side Chain. 
2. Substitution on the Pyridone Nitrogen61 
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The primary pyridone, 13, was the most potent among variations examined at R2.  
Other compounds displayed a loss of potency in both isolated enzyme and in cellular 
assays when compared to compound 9 (table 5). 
Compound R2 Cascade 
IC50(µM) 
Cellular 
IC50(µM) 
9 NH2 0.023 0.004 
13 H 0.100 0.63 
 
Table 5: Substitution on the Pyridone Nitrogen. 
 
3. Replacement of the 4′-Iodide61 
The 4′-iodide was replaced with various halogens and/or alkyl groups to examine the 
contribution of the 4′-iodide to MEK1 activity when the molecule also contained the 
pyridone acyl as an H-bond acceptor in the central ring (table 6). 
 
Compd R1 R3 Cascade 
IC50(µM) 
Cellular 
IC50(µM) 
9 NH2 2-F-4-I 0.023 0.004 
14 NH2 2-F-4-CH3 2.97 -- 
15 NH2 2-F-4-Br 1.91 0.093 
16 NH2 3,4-dichloro 5.72 3.9 
 
Table 6: Replacement of the 4′-Iodide. 
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From the results obtained, it was clear with hindsight that the interaction between the 4′-
iodide and the lone pair of the backbone amide acyl of Val127 (evidenced in both the 
MEK1 and MEK2 X-ray crystal structures) was critical to the activity of this series of 
MEK1/2 inhibitors. 
1.10.1 Development of Mekinist from the 4-(phenylamino)-5-carboxamido-2-
pyridones60 
 
Compound 17 was identified by high-throughput screening based on the previous studies 
which showed 4-(phenylamino)-5-carboxamido-2-pyridones to be potent MEK inhibitors. 
It was shown to have an anti-proliferative activity against human cancer cell lines ACHN 
and HT-29 with IC50 values of 4800 and 990 nM respectively.  However, due to the high 
hydrophobicity of the molecule (ClogP 6.3)60, SAR studies were conducted and led to 18 
which displayed improved potency 4-fold and a bit reduced hydrophobicity (ClogP 
5.0).60 
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Figure 27: SAR studies on 17 and development of 18.60 
To further increase the potency, substitution on the aniline ring was examined and 
various alkyl groups and halogens were prepared.  Variations on the heteroaromatic core 
were also conducted to generate the highly potent 19.  Unfortunately compound 19 also 
displayed very low aqueous solubility and high hydrophibicity (ClogP 6.0). 
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Figure 28: Substitution on the aniline and heteroaromatic core transformation.60 
Substitutions were tried on the indicated phenyl ring on the heterocyclic core of 19 with 
more polar groups was examined to optimize the aqueous solubility and oral 
bioavailability while improving potency if possible (Figure. 29). GSK1120212, 
Mekinist, shown as compound 20 was developed as the DMSO mono solvate.  It showed 
good primary activity, desirable solid state properties, oral bioavailability and acceptable 
although not ideal aqueous solubility. 
 
Figure 29: Polar group (R) substitution SAR let to the development of GSK1120212.60 
 
Compound-immobilized affinity chromatography with compound 20, identified MEK1/2 
as the target kinase.70  Starting from an initial lead 17, SAR studies led to the discovery 
of 20, GSK1120212 (JTP-74057 DMSO Solvate), a highly potent, selective, and orally 
active MEK inhibitor.  It also displayed a remarkable potency in cellular assays for 
ERK1/2 phosphorylation and growth inhibition.  Significant dose-dependent tumor 
growth inhibition was observed for a span of 21 days of daily oral administration.60 
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Mekinist (GSK1120212) (trametinib) was approved in May of 2013 for use in treatment 
in melanoma patients with BRAF V600E or V600K mutation either alone or with co-
administration with Dabrafenib (tafinlar).30a  Dabrafenib is a BRAF inhibitor with 
IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF 
V600D mutants, respectively. 
8.3 Other MEK inhibitors 
PD98059 and U0126 were early compounds developed to be selective MEK1/2 pathway 
inhibitors (Figure 30).  Full characterization of their specific biological interactions has 
not been published to date.  These compounds do not compete with ATP for binding in 
isolated enzyme preparations.  Both compounds, U0126 and PD 980595, display 
competitive binding with each other and were assumed to be interacting at single or 
adjacent site.6a, 71  
U0126 inhibited MEK1 in a dose dependent fashion with an IC50 of 0.072 µM.
44b, 71a  
Both compounds were later shown to poorly inhibit the MEK5/ERK5 kinase cascade in a 
cellular assay.72 
 
Figure 30: MEK1/2 inhibitors U0126 and PD98059.44b 
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Chapter 2 
 
Chemical Literature Review 
 
The chemistry required for this project can be divided into several discreet categories:  
aryl bond formation to generate the diphenyl amine portion, amide bond formation, and 
supporting chemistry. 
 
2.1 Aryl bond formation to generate Diphenylamines 
 
The formation of aryl-nitrogen bonds has been recently reviewed.73  The strategies for 
forming an aryl-nitrogen bond has its origins back in 1903 with one of the oldest methods 
to synthesize diarylamines reported by Fritz Ullmann (Scheme 1).74  These Ullmann 
coupling reactions utilized an aryl halide and an aryl amine along with copper and base to 
form an aryl-nitrogen bond.  Recent variations of the Ullmann reaction have been 
published75 and modern developments include the use of solvating and activating ligands 
for the metal, the use of less-reactive electrophilic aryl partners, and the development of 
methodologies that require less forcing conditions: lower temperature, weaker bases, 
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shorter reaction times, and the use of microwave heating to both increase yield and 
reduce side reactions.  The rationale for these strategies are to permit greater aryl ring 
variation.  The reaction is proposed to proceed through oxidative addition into the aryl-
halide bond, followed by ligand displacement by the aryl amid, to yield the final product 
by reductive elimination of the metal atom.  The specific pathway, or more correctly 
pathways, is (are) still undergoing analysis to confirm the mechanism(s).  In certain 
conditions near quantitative yields have been obtained, although reactions with much 
lower yields are more typical.   
Specifically, Ullmann reported the reaction of aniline with 2-chlorobenzoic acid in the 
presence of stoichiometric amount of copper to give 2-phenylaminobenzoic acid.74b 
 
Scheme 1: Synthesis of diarylamines by Ullmann Coupling. 
Irma Goldberg in 1906, showed that the reaction occurred in the presence of catalytic 
amounts of Cu (Scheme 2).76  Of particular note for this conversion is that the relative 
electron flow for the Goldberg variation of the Ullmann coupling has an electron flow in 
the reverse direction.  This raises the possibility that there may be multiple reaction 
mechanisms for the “Ullmann” reaction, an observation that is still providing ample 
opportunity for inquiry.  Practically, this gives the experimenter wide latitude for 
variation of reaction precursors to yield the desired product. 
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Scheme 2: Goldberg synthesis of diarylamines in 1906.76 
Additional metal-mediated couplings have been discovered including palladium, nickel, 
iron and other metal couplings.  Of particular note is the development of the Buchawld-
Hartwig palladium couplings.77  This conversion was originally conceived by Hartwig 
but brought to practical utility by Stephen Buchwald.78  In 2002, Buchwald  developed a 
more efficient palladium catalyst systems for the amidation79 shown below. (Scheme 3).  
The adequate solvation of all oxidation forms of the palladium atom, the development of 
metal/ligand complexes that were more stable to the presence of trace amounts of 
molecular oxygen, and optimization of the base employed were all advances that brought 
this reaction from an interesting synthetic observation to a widely-used synthetic 
methodology. 
 
 
Scheme 3. Synthesis of diphenylamines using Buchwald Coupling.79 
This methodology continues to evolve with an emphasis on new nitrogen sources, 
improved catalytic turnover achieved by well-solvated pre-catalysts, and the design of 
more efficient ligands.  These reactions require an electron-rich aryl nitrogen and a 
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coupling aryl partner that can readily undergo oxidative palladium insertion.  In general, 
the Buchwald-Hartwig couplings are recommended for aryl groups with substitutions that 
would be incompatible with the more rigorous Ullman coupling conditions. 
In addition to these metal-mediated couplings, ionic SNAr reactions with an appropriately 
matched nitrogen nuclophile and haloarene behaving as an electrophile have been 
successfully developed.80  These conversions continue to be explored as useful strategies 
to form aryl-nitrogen bonds80-81 and find additional utility in forming di-aryl ethers80, 82, 
and di-aryl thioethers.80, 81c-f, 83  These SNAr conversions require a very nucleophilic aryl 
nitrogen atom, typically prepared by deprotonation using an Na+, Li+, or K+ containing 
strong base.  The pKa for these anilines are typically in the 15-25 range so NaH, 
NaHMDS, LiNH3, LiHMDS, KH, KOt-Bu, or KHMDS are commonly employed.  
The electrophilic partner must be electron deficient and be able to stabilize the proposed 
sp3 transition state of the SNAr mechanism.  Ortho-halo heterocycles are commonly 
encountered in this reaction class.  Arenes with ortho-substitution by strongly electron-
withdrawing groups are also frequently encountered.  Specifically, ortho nitro 
haloarenes,81a, 81f, 84 and multiply-halogenated arenes are commonly used successfully for 
this reaction. 
A specific recent example is the conversion by Davis et al.85 that uses the SNAr reaction 
to develop a novel route of synthesis of diphenylamines utilizing LiNH2 (Scheme 5). 
This route utilizes a less-common, but commercially available base LiNH2.  They then 
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surveyed both activated or unactivated aryl halides.85  
 
Scheme 4: Synthetic route for diphenylamines utilizing LiN(iPr)2. 
A specific goal and significant finding of this work is that the lithium cation directs the 
ultimate regioselectivity of this conversion by preferential attack of the aniline anion to 
the ortho- position of the carboxylic acid. Coordination of the lithium cation with the 
carboxyl group and the leaving group were postulated as coordinating both the attack and 
elimination, resulting in a kinetic preference for the  ortho substitution product.85 
 
Scheme 5. Synthesis of diphenylamine 39 utilizing LiNH2.
85 
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Figure 31: Li+ ion directs the attack of the aniline anion to the ortho position of the 
carboxylic acid. 
Attack at the 3-fluoro atom was less likely arising from the absence of a reasonable 
resonance form with the carboxylate.  Attack at the 4-fluoro atom would be lacking any 
coordination possible, but in the absence of the Li+ coordination effects, could 
conceivably be as electrophilic as the 2-fluoro atom.  Davis confirmed this by using 
NaNH2 which did give a mixture of the 2 and 4 substituted produces.  Additionally Davis 
found that only 2-iodo benzoic acid and not 4-iodo benzoic acid was reactive under the 
experimental conditions examined using LiNH2. 
 
2.2 Amide bond formation to generate Acyl variations 
The final relevant chemical conversion is the synthesis of a series of amide molecules. 
Many peptide coupling reactions have been reported for the formation of the amide 
bonds.86  A recent critical review that examines the utility and limitation of many 
common methods of amide bond-forming strategies provides a convenient basis for 
surveying strategies employed in this work.86  In general, the carboxylate is activated to 
convert the relatively weak “OH” group into a better leaving group.  Common general 
strategies include replacement of the OH of a free carboxylic acid with its ester, 
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conversion of the “OH” to a halide anion (acid halide formation), conversion of the “OH” 
into a carboxylic acid (anhydride formation), conversion of the “OH” into a urea (use of a 
carbodiimide or uronium reagents), and conversion of the “OH” into a phosphate 
(phosphoric acid anhydride and BOP-type reagents).  These strategies are listed in order 
of increasing cost and increasing complexity.  The development of multiple different 
amide bond forming strategies has been driven by the need to have reagents that are 
reactive, suppress side reactions (specifically loss of stereochemical integrity at the -
carbon of -amino carboxylic acids), cost-effective, and have an easy isolation of the 
desired product from the side products.  Practically there is always a compromise the 
must be reckoned with during the selection of an amide bond formation reaction strategy.  
Many times the selection of a specific synthetic strategy or reagent is determined by the 
specific substrates utilized.   
One efficient approach is conversion of an acid to its corresponding acid chloride, and 
then reacting this now activated acyl with the desired amine to form the required amide. 
This reaction usually proceeds at room temperature and employs relatively mild reaction 
conditions.  Potential disadvantages of using an acid chloride to form an amide include: 
a) generation of very reactive species which is highly moisture sensitive, b) the 
establishment of acidic reaction environment which makes it unsuitable for acid labile 
functional groups, c) the possibility of ketene formation if an -proton is present and a 
sufficiently strong base (pKa 9 or greater) is used, and d) the likely loss of stereochemical 
integrity if the -carbon has a proton and is stereogenic. 
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Scheme 6: Synthetic scheme of amides via acid chloride. 
 
Scheme 7: Mechanism of chlorination by oxalyl chloride or phosgene. 
Many chlorinating reagents have been reported and the most commonly used are given in 
table 7. 
For some of the compounds required, the formation and use of an acid chloride coupling 
strategy was found to be a useful strategy.  Factors considered for choosing this approach 
included: the need to significantly activate the carboxylic acid due to its low capacity for 
nucleophilic attack on the peptide coupling reagent, a decreased likelihood for attached 
nitrogen atoms to attack the acyl chloride during the course of the reaction, cost of the 
reagents, precedent, reproducibility, the absence of either a stereogenic -carbon or an 
extractable -proton, and ease of isolation. 
 
 
 
 53 
Entry Reagent Structure 
1 Thionyl chloride87 SOCl2 
2 Oxalyl chloride88 
Oxalyl chloride with Cat. DMF 
 
3 Phosgene89 COCl2 
4 Triphosgene90 
 
5 Pivaloyl chloride91 
 
6 Phthaloyl chloride92 
 
7 TPP93 PPh3/CCl4 
 
Table 7: Commonly used chlorinating agents. 
 
For some of our compounds, the use of a carbodiimide reagent such as DIC and urea-
forming coupling strategy was required. 
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Scheme 8: Mechanism of carbodiimide coupling. 
 
Scheme 9: DIC coupling reaction. 
Several of the most commonly used carbodiimide coupling reagents are given below.  Of 
the many carbodiimdide reagents commercially available, DIC and EDCI were found to 
have an appropriate combination of reactivity, cost, and ease of isolation that recommend 
their use.  The use of a carbodimide coupling strategy was most commonly necessary 
when the nitrogen atom of the diphenyl amine was sufficiently electron rich to begin to 
attack the acid chloride during the reaction if an acid chloride coupling strategy was 
attempted.  Thus the carbodiimide strategy was employed when the acid chloride 
coupling strategy gave a complicated mixture of non-desired products.  
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Entry Abb. Structure 
1. DCC94 
 
N,N’-dicyclohexylcarbodiimide 
2. DIC95 
 
N,N’-diisopropylcarbodiimide 
3. EDCI95 
 
N-ethyl-N’(3-dimethylaminopropyl)carbodiimide 
4. CIC96 
 
N-cyclohexyl, N’-isopropylcarbodiimide 
5. PIC97 
 
N-phenyl, N’-isopropylcarbodiimide 
 
Table 8: Carbodiimide coupling reagents. 
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Chapter 3 
 
Statement of the Problem 
 
3.1  MEK5 
Goal of the research 
The goal of this research is to develop potent and selective inhibitors of MEK5 to 
establish better characterization of the functional role of MEK5 both in vitro and in vivo. 
The goals for designing and synthesizing the target compounds are: 
 To increase H2O solubility 
 To simplify the structure of the compounds and improve ligand efficiency98 
 To establish structural requirements for MEK5 versus MEK1 selectivity 
 To validate the homology model 
 
Hypothesis: 
 
MEK5 is one component in a signaling pathway that permits cells to survive oxidative 
stress and is activated by various mitogens (EGF and G-CSF), cytokines (LIF and CT-1), 
or stress (H2O2 and sorbitol). MEK5 is significantly up-regulated in response to stress 
including ionizing radiation, palyotoxin, and phorbol ester treatment. These stressors, 
both external and internal typically activate a cascade of intracellular signaling events. 
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Usually, multiple pathways are activated concurrently. The phosphorylation of various 
ERKs by their associated MEKs represents a uniquely parallel event in the signaling 
cascade. Our hypothesis is that these MEKs represent a non-redundant array of gates for 
mitogen-activated physiological responses. Development of MEK knockout or 
knockdown models have not been successful due to either lethal or adaptive phenotypes. 
Thus the development of small molecule inhibitors could permit analysis of the role of 
each MEK across multiple animal models. MEK1 has been the focus of extensive study 
with Type III inhibitors. MEK5, by contrast has received little attention despite its 
significant up-regulation in cancers and its up-regulation to oncogenic stimuli. (Figure 
32). 
 
Figure 32: The MEK5 signaling cascade.99 
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The need for going towards Type III inhibitors:35 
A high degree of sequence homology is displayed amongst the catalytic domain or the 
ATP binding site of kinases. The activation loop above the ATP binding site is highly 
conserved and thus it is a significant challenge to achieve selectivity by targeting the 
ATP-site. The Type III inhibitor site is largely a hydrophobic binding pocket outside of 
the ATP binding site that has been recognized as having the potential for inhibitory 
kinase activity.  Exploration of the type III binding site is a new pharmacological strategy 
to inhibit kinases that has only appeared within the last 3 years, and has only been applied 
to non-MEK1 kinases until very recently.  The rational design and synthesis of type III 
site kinase inhibitors provides a recently emergent opportunity for achieving kinase 
selectivity of protein kinases requiring phosphorylation for T-loop activation.  The 
synthesis of type III inhibitors for the various MEK isoforms, initially MEK5, will assist 
in discerning the biological role and relevance of these signaling cascades that are 
indicated in significant human pathological states. 
 
Lead compounds: 
CI-1040 (4) and PD325901 (5) were developed by Pfizer in the early 1990’s as MEK1/2 
inhibitors with the goal of developing orally-active anti-cancer agents.61-62  These were 
subsequently found by the Cavanaugh lab to inhibit MEK5 as well.  Both CI-1040 and 
PD325901 have been presented as Type III or allosteric site inhibitors on the basis of X-
ray crystallographic analysis with MEK1 and these compounds have progressed into the 
clinical trials. CI-1040, however suffered from poor aqueous solubility and rapid 
clearance.100  SAR studies led to the development of PD325901 wherein the 2-
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orthochloro was replaced by 2-orthofluoro and the hydroxamate side chain was modified 
for better pharmacokinetic properties such as solubility and bioavailability.66  PD325901 
entered clinical trials for the treatment of advanced non-small cell lung cancer; however 
clinical trials were terminated due to the occurrence of ocular and neurological toxicity 
(ClinicalTrials.gov Identifier: NCT00174369).  It has been found that these toxicities are 
currently believed to reside in MEK2 inhibition in the outflow of the retinal pigment 
epithelium and results in local increase of luminal pressure in retinal veins.101  The 
activity and side effects of PD325901 underscores our hypothesis that understanding the 
MEK isoform selectivity of specific inhibitors and understanding the in vivo 
pharmacology are essential goals both for discerning direct activity as well as indirect 
toxicity. 
Name Stage of 
development 
Frequency of 
ocular toxicities 
Description of ocular 
toxicities 
IC50 
for 
MEK 
CI-1040 Discontinued 6 (9%) out of 67 
(Phase II) 
Blurred vision, altered 
light perception.63 
17 
nM62a 
PD-0325901 Discontinued 9 (14%) out of 66 
(Phase I) 
5 (38%) out of 13 
(Phase II 
continuous) 
1 (5%) out of 21 
(Phase II 
intermittent) 
Visual disturbances, 
including 2 cases of 
RVO.102 
Blurred vision.103 
1nM62c 
Trametinib 
(Mekinist) 
(GSK1120212) 
FDA 
approved in 
2013 
Unknown (Phase 
I) 
Unknown (Phase 
I melanoma) 
Unknown (Phase 
II) 
2 dose limiting central 
serous retinopathies 
2 cases of dry eye, 2 
cases of blurred vision 
2 cases of central 
serous retinopathy 
3.4 
nM104 
 
Table 9: Ocular toxicities of MEK inhibitors. 
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Name Stage of 
development 
Frequency Description IC50 
BRAF 
mutant 
Dabrafenib 
(GSK2118436) 
Phase III None reported 
(Phase I) 
NA105 0.16 
nM 
 
Table 10: Ocular toxicity of BRAF inhibitor Dabrafenib. 
 
Recently, CI-1040 finished a multicenter phase 2 Study of CI-1040 in patients with 
advanced nonsmall-cell lung cancer, breast cancer, colon cancer or pancreatic cancer 
(ClinicalTrials.gov Identifier: NCT00033384) (Figure 33).  Also, the first MEK1/2 
inhibitor ‘Mekinist’ (trametinib) was approved in May of 2013 for use in treatment of 
patients with unresectable or metastatic melanoma with a BRAF V600E or V600K 
mutations either alone (assuming the absence of prior therapy with a BRAF inhibitor) or 
with co-administration with Dabrafenib (Tafinlar) (Figure 34).  It has recently been 
suggested that the synergistic effects with dabrafenib may be the result of BRAF 
mutations resulting from partial inhibition of MEK2 which permit the development of 
therapeutic resistance through BRAF mutations. 
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Figure 33: MEK1/2 inhibitors and the lead compounds. 
 
Figure 34: BRAF inhibitor Dabrafenib (Tafinlar). 
 
3.2  Construction of the homology model 
The primary protein sequence of MEK5-β-DD (S311D and T315D) (Q13163)106 was 
aligned with the structure of MEK1 (PDB: 3EQC: 1.8 A resolution) using Acelrys 
Discovery studio 2.5.1. The two structures indicated good overlap of the DFG and HRD 
sequences, DOPE score and Ramachandran plot analysis. 
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Figure 35: ATP and Type III binding site in MEK1 crystal structure and superimposed 
homology model of MEK5.107 
 
 
Figure 36: Type III inhibitor docked in 3EQC.107 
PD325901 (5) was docked into the homology model of MEK5DD and made reasonable 
interactions with adjacent residues (Figure 35).  An analysis of the amino acid residues 
that were proposed to converge to the Type III site by the homology model indicated that 
the portion of MEK5DD with the right aniline ring could be a source of possible 
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difference between MEK1, 2, and 5.  Subsequent CLUSTAL analysis of all 7 canonical 
MEK isoforms is consistent with this initial analysis (see Appendix).  The glycerol side-
chain of PD325901 was originally developed by Pfizer as a surrogate for the triphosphate 
of ATP with the simultaneous goals of increasing water solubility and potency.  
However, upon analysis of the MEK1 structure of 3EQC, it was observed that the binding 
domains of ATP’s triphosphate and the binding domain of the glycerol portion 
represented different and non-overlapping portions on the surface of MEK1.  The 
glycerol portion of PD325901 was found to extend into the solvent and although it did 
increase water solubility, both the more complex synthesis of the hydroxamic acid ester 
and the toxicity of this group recommended truncation back to the amide.  Further 
analysis and ligand design from the amide portion of the molecule attempted to combine 
both increased interaction with the MEK5DD surface with better water solubility into 
the same functional group. 
Evaluation of initial compounds during development of the homology model suggested 
the compound (Figure 37) as one of the most selective MEK5 inhibitors.  This 
compound was bound into the MEK5βDD homology model using both MOE dock and 
by structural variation from PD325901. 
 
Figure 37: Most selective MEK5 inhibitor from our initial studies (synthesized by 
Ishveen Chopra). 
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Figure 38: Ligand specific interactions plot of compound 56 in MEK5 homology model. 
Analysis of interaction of the ammonium nitrogen of 56 suggested potential interaction 
with Asp283 (3.71 Å) and adjacent polar residues through a complex web of interactions 
(Figure 38).  Thus the N-methyl piperidine moiety was retained with the premise that it 
contributed to both increased interaction with the MEK5DD surface (on the basis of 
post-testing rationalization using the MEK5DD homology model) and better water 
solubility due to probable ammonium ion formation at physiological pH (~ 7). 
 
The designed compounds were proposed as MEK5 type III (allosteric) inhibitors derived 
from the known MEK1/2 inhibitor PD325901, biological testing, and our MEK5DD 
homology model. 
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3.3  Specific goals: 
The diphenylamine moiety was selected as the core because it exists in the PD325901 
structure, provides rapid synthesis, and allows structural variation in locations what were 
proposed as being both interesting and potentially useful for modification. The major 
modifications tried were: 
 
 
 
 
1. Side chain variation and amide variation: 
 
I: Side chain variations 
• Increase aqueous solubility 
• Examine MEK5 predicted interactions 
 
II: Amide variations 
III: Central arene  
• Establish minimal necessary substitution 
• Predict MEK5 selective interactions 
 
IV: Terminal arene   
• Establish minimal necessary substitution 
• Predict MEK5 selective interactions 
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This is the last synthetic step and represents the most useful point of structural 
diversification.  Goals were to increase interaction with the MEK5DD surface (using the 
assistance of the MEK5DD homology model) and increase water solubility.  Proposed 
variations included basic amines with various alkyl length linkers (both cyclic and 
acyclic); these were designed to interact with acidic and polar resides unique to MEK5 
versus MEK1.  Sidechain variations examined also included synthetic precursors 
(amides, acids, tert-butyl carbamates) and characterized side-products. 
 
2. Target compounds with de-iodo diphenylamine: 
 
 
 
3. Target compounds with no halogens on the terminal arene ring: 
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4. Central arene variation: 
Prior literature61 indicated that the 3 and 4 fluorine atoms, although present on the lead 
compound PD325901, functioned as more than just electron-withdrawing groups.  It has 
been proposed that the 4-fluorine atom, forms an electrostatic or hydrogen bond 
interactions with the Ser212 of the C-helix.  With an eye toward the eventual design and 
synthesis of more novel central arene variations, an initial survey of the need and utility 
of fluorine atom substitution for MEK5 inhibition was conducted. 
 
5. Terminal arene variation: 
In a manner analogous to the narrative above, terminal arene variations were prepared to 
survey of the need and utility of fluorine and iodine atom substitution for MEK5 
inhibition.  Of particular note, the 4’-iodide atom presented multiple sub-ideal chemical 
features: high molecular weight (126 Da), large hydrophobic area, and potential photo-
instability.  However, the 4’-iodidophenyl moiety is scrupulously retained in all 
compounds that were advanced in the design of MEK1inhibitors; ultimately this 4’-
iodidophenyl moiety is present in the structure of the FDA approved MEK1 inhibitor 
Mekinist. 
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6. Variations on the nitrogen atom of the diphenylamine: 
Analysis of the deposited X-ray crystal structures of MEK1/2 type-III inhibitors indicated 
the unvarying presence of secondary amines at this position.  Additional analysis 
indicated a geometry of the heavy atoms identified in the deposited X-ray crystal 
structures consistent with internal hydrogen bonding into a 6-membered ring.  Given the 
rigorous retention of the 4’-iodidophenyl moiety in all MEK1 inhibitors, it was unclear if 
the highly plausible internal bond from the aniline NH to the acyl lone pair was necessary 
or useful either for MEK1 or MEK5.  The initial compound slated for synthesis to 
analyze the contribution from internal hydrogen bonding was the acid: the N-methyl 
diphenyl aniline acid analog, compound 76.  This compound is unable to participate in 
internal H-bonding and although introduction of the N-methyl group would certainly 
result in additional structural variation, this was viewed as both the most accessible and 
the most useful first step towards analyzing the contribution of internal hydrogen bonding 
toward MEK1 or MEK5 activity. 
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Figure 39: The presence of the N-methyl changes the conformation of the molecule 
which otherwise had an internal hydrogen bonding leading to a more conformationally 
restricted analog. 
 
3.4  Results:  
For the design and synthesis of MEK-5 inhibitors, medicinal chemistry strategies 
included: an initial lead and analog design, modification of known Type III MEK-1/2 
inhibitors, and computer-assisted design based on a MEK5DD homology model. 
Compound 72 was identified as a selective inhibitor of MEK5 mediated phosphorylation 
of ERK5 in MDA-MB-231 triple negative breast cancer cells, and will be examined in 
mouse tumor xenograft models. 
 
 
 
 
 
 70 
Chapter 4 
 
Chemical discussion 
 
As presented in the statement of the problem, variations were desired at multiple 
locations on the core structure of the diphenylamine.  Although it was initially envisioned 
to use a single synthetic strategy to prepare all compounds, in practice it was found 
necessary to use the most appropriate synthesis strategy for each compound required.  
Although these required variations in synthetic strategy were determined experimentally, 
in hindsight these required variations can be readily understood on the basis of 
understanding the reaction mechanism. 
 
Synthesis of the tetrahalo core: 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid (39). 
Synthesis of the tetrahalo diphenylamine core, 39, was achieved with the lithium amide 
displacement approach (Scheme 10) of Davis et al.85  This procedure was scaled up to a 
4 gram quantity which was necessary for the desired animal experiments with compound 
57 (SC-1-151). 
 
 71 
 
Scheme 10: Lithium amide displacement approach. 
Preferential substitution occurs at the ortho-position as indicated above and as identified 
in the literature.85  The regioselectivity of the addition can be rationalized along the 
following lines.  First, ionic interaction of the carboxylate-oxygen anion and the lithium 
cation is very likely to occur.  This ionic chemistry can be observed experimentally as the 
initial exotherm noticed as the lithium amide abstracts the carboxylate proton to form the 
ionic lithium carboxylate.  This species is well solvated in the reaction solvent, THF.  
Davis et al.85 have postulated that the lithium cation associated with the carboxylate 
coordinates with, and directs, the aniline anion towards the ortho-position of the 
carboxylate to facilitate initial nucleophilic attack at the fluorine bearing number 2 
carbon.  The 2-carbon is significantly electron deficient due to the attached fluorine atom, 
the adjacent fluorine atom, but most significantly due to the ortho carboxylate.  The ortho 
carboxylate can withdraw electron density from the number 2 carbon through both 
inductive and resonance effects.  Inductive effects are decreased by the inverse square of 
distance suggesting that the 2-carbon would be the most electrophilic carbon of lithium 
2,4,5-trifluorobenzoate  In support of this postulate, Davis indicates that similar 
conditions were successful for nucleophilic attack of lithium (2-fluoro-4-
iodophenyl)amide on 2-fluroro-benzoic acid, while nucleophilic attack of lithium (2-
fluoro-4-iodophenyl)amide on 2-fluroro-benzoic acid was unsuccessful.  Additionally 
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this method was used to prepare compounds that were co-crystallized in the structure of 
MEK1.  The chemical (1H NMR, elemental analysis) and physical properties were 
identical with the literature values.   
However, additional confirmation for the regioselectivity was sought.   Acquisition of the 
19F NMR spectra of 2,3,4-trifluorobenzoic acid, 2-fluoro-4-iodoaniline, and 3,4-difluoro-
2-((2-fluoro-4-iodophenyl)amino)benzoic acid was conducted using the hetero-nuclear 
broad-band probe on the 500 MHz instrument. 
 
Synthesis of the tetrahalo amides. 
The simple amides were envisioned as being readily prepared by the addition of the 
appropriate amine into the acid chloride that could be prepared from the carboxylic acid 
39.  This acid, 39, was found to be readily converted into the corresponding acid chloride 
(Scheme 11).  The reagent of choice was oxalyl chloride and catalytic DMF.  This 
system utilized the addition of neat oxalyl chloride to the reaction mixture containing the 
acid, DMC, and catalytic DMF.  The functional role of the DMF is to generate the 
chloridinium intermediate as shown below.  This chloridinium species (84) then activates 
the carboxylic acid to produce the acid chloride.  This reaction proceeded at diffusion-
limited rates at 0 oC indicated by the rapid formation and loss of the yellow chloridinium 
species (Scheme 12).  Overall the reaction was completed within 2 hours at or below 
room temperature to consistently generate acid chloride 79. 
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Scheme 11: Acid chloride formation. 
 
 
Scheme 12: Mechanism of acid chloride formation. 
 
Reaction of the acid chloride, 79, with the desired amines to yield the desired amides was 
not always straight-forward as originally planned.  
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Scheme 13: Synthesis of simple amides using the acid chloride method. 
In case of amides bearing a basic amine, this method was not successful. Although the 
starting acid chloride was consumed, many TLC spots were obtained and the product 
could not be isolated using routine silica gel column chromatography. The addition of a 
base -such as TEA- along with the precursor amine in the reaction mixture was examined 
and was only modestly successful in a few cases, albeit with poor yields. Table 11 below 
summarizes the different conditions (reagents and equivalents) examined in an attempt to 
optimize the yield for this synthetic strategy. 
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Precursor 
amine 
Equivalents  
of amine 
Reagents Solvent Reaction 
Conditions 
Result 
 
2.54 mmol/ 2 eq. TEA, DMAP DCM 25 oC, 4 h 44%* 
 
6 mmol/ 2 eq. DMAP DCM 25 oC, 12 h, Could not 
isolate the 
product 
2.64 mmol/ 3 eq. TEA, DMAP DCM 25 oC, 12 h 40%* 
 
5 mmol/ 10 eq NaHCO3, 
DMAP 
DCM 25 oC, 12 h Could not 
isolate the 
product 
3.55 mmol/ 1.18 
eq 
DIEA, DMAP DCM 25 oC, 12 h Could not 
isolate the 
product 
3.46 mmol/ 2 eq. DMAP DCM 25 oC, 6 h 6 %* 
 
8.04 mmol/ 3 eq. TEA, DMAP DCM 25 oC, 12 h Could not 
isolate the 
product 
 
* = Chemical yield based on mass of isolated product. 
Table 11: Different reaction conditions with different precursor amines. 
Several possibilities could exist to explain the low yields.  In many cases isolation of the 
compound from the column was difficult due to the basicity of the product amine. 
An intractable complex mixture resulted if excess starting amine was used. Presence of 
moisture may also have complicated both identification and isolation of the product from 
the crude.  
Finally it was decided to use DCC108 (Scheme 14) and DIC95 (Scheme 15) coupling to 
form the aide bond more efficiently.  In all cases the use of DCC presented a complex 
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mixture which did not permit isolation of clean product.  In most cases reactions with 
DIC proceeded well with a comparatively better cleanup than with DCC. 
 
 
Scheme 14: DCC coupling reaction. 
 
Scheme 15: DIC coupling reaction. 
 
Synthesis of the trihalo core: 3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid 
(68). 
Synthesis of 3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid , or the de-iodo 
variant of diphenylamine acid 68, was initially attempted directly from 39 using the 
standard Pd/C reductive de-iodination109.  However, only starting material was recovered, 
with no evidence of conversion by either TLC or 1H NMR.  Although this conversion 
could have been pursued, the reliable yield for addition of 2-fluoro-4-iodioaniline into 
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2,3,4-trifluorobenzoic acid recommended a direct synthesis for compound 68 using the 
procedure of Davis85.  
 
Scheme 16: Pd/C reductive de-iodination reaction. 
The desired carboxylic acid 68 was then prepared successfully using the lithium amide of 
2-fluoroaniline in an SNAr displacement on 2,3,4-trifluorobenzoic acid.  This conversion 
proceeded in 59% isolated yield. 
 
 
Scheme 17: Lithium amide displacement method. 
For the formation of the methyl piperazine amide 69, and in an attempt to streamline the 
isolation, particularly for basic amine variants, a T3P coupling was tried (Scheme 18). 
The crude TLC indicated a number of spots which could not be separated using column 
chromatography. This reagent was not pursued further. 
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Scheme 18: T3P coupling reaction. 
An EDCI coupling was subsequently used successfully and the fumarate salt of the 
product 69 was isolated (Scheme 19).  The side product urea from EDCI was removed 
more effectively than the side product from the DIC coupling permitting a clean isolation 
of the basic amine containing product.  Formation of the fumarate salt was required 
because the free base form of the compound was difficult to solidify and recrystallize, as 
a result direct elemental analysis on the product was unsuccessful.  Formation of the HCl 
salt of 69 produced a very hygroscopic compound that could not be adequately dried to a 
free-flowing solid.  The formation of the fumarate salt addressed isolation and 
characterization of the desired product in a simple efficient manner. 
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Scheme 19: Synthesis of 69 Fumarate by EDCI coupling. 
 
The primary amide derivatives of various terminal ring variations were also synthesized 
and are described below. 
 
Synthesis of the dihalo core: 3,4-difluoro-2-(phenylamino)benzoic acid (71). 
The dihalo core, 3,4-difluoro-2-(phenylamino)benzoic acid,  retained the central 3,4-
difluoro phenyl ring but varied by the lack of halogens on the terminal arene ring.  This 
compound was prepared by the lithium amide displacement method previously described 
in 43 % isolated yield.85  
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Scheme 20: Synthesis of 71 using lithium amide displacement method. 
 
Synthesis of the dihalo amides. 
Again although the general synthetic strategy proceeding through the acid chloride of 
carboxylic acid 71 did work, there were complications.  The chemical route beginning 
with the dihaloacid 71 was lower yielding than with the previously described tetrahalo 
acid 39.  A possible explanation is that the attached diphenyl amine was less electron 
deficient for 71 than for 39.   Although the carboxylic acid 71 was anticipated to react in 
a manner analogous to the tetrahalo acid 39 described above, the less electron deficient 
diphenyl amine may have participated in side reactions including intra- or inter-molecular 
condensation of the diphenyl amine with the acyl chloride.   
Additional synthetic difficulties were encountered in this series during the preparation of 
the piperazine derivatives.  The desired Boc-piperazine (91) amide was made 
successfully albeit with 20% yield, however deprotection with 4N HCl and subsequent 
Eschweiler-Clarke alkylation, as shown below did not work. A complex crude mixture 
was obtained with many spots on silica TLC possibly due to the formation of the 
dimethylated compound along with the unreacted starting acid.  Also the presence of the 
basic amine presented extreme isolation challenges.  Deprotection of the Boc group and 
isolation of the resultant TFA salt was also tried, but the product could not be isolated 
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(Scheme 21).  Hence, an EDCI coupling reaction was tried between the carboxylic acid 
71 and N-methyl piperazine, compound 72; the free base of the desired product was 
isolated in 61% yield (Scheme 22).  A possible explanation for the success of this 
strategy is that the carbodiimide coupling circumvented the self-condensations described 
above.  The direct use of N-methyl piperazine was particularly useful.  At the beginning 
of this project it was unclear if the secondary amine or tertiary amine variations of acyl 
piperazine would be more active.  The SAR emerged in such a way that the tertiary N-
methyl piperazine containing amide, compound 72, was actually more active.   As a 
result, direct synthesis of the N-methyl piperazine containing amides was established as 
the preferred synthetic strategy, regardless of amide formation used. 
 
 
Scheme 21: Eschweiler-Clarke reaction approach towards the synthesis of 72. 
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Scheme 22: EDCI coupling for the synthesis of 72. 
Additionally, the primary amides of these derivatives were also prepared as shown in 
scheme 23.  The synthesis of compound 73 was unsuccessful and will the focus of 
additional work by another student. 
 
Scheme 23: Synthesis of the primary amides 57, 73 and 70. 
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Synthesis of the unhalogenated core: 2-(phenylamino)benzoic acid. 
Initial attempts for synthesis of unhalogenated diphenylamine acid (25) scaffold: 
Both lithium amide and sodium hydride SNAr reactions were attempted and did not work.  
One possible explanation is that in case of the synthesis of diphenylamine analogs 
containing no halogens on either of the arene rings that the carbon halogen bond was not 
adequately polarized to facilitate an SNAr attack from the amid salt.  
 
Scheme 24: Sodium hydride SNAr reactions for the synthesis of 25. 
 
 
Scheme 25: Lithium amide SNAr reaction for the synthesis of 25. 
 
Due to the different substrates required for the desired analogs, a different synthetic 
strategy was necessary.  A survey of different aryl to nitrogen coupling strategies was 
conducted (see prior description).  Ultimately an Ulllmann coupling strategy using the 
addition of an aniline into the carbon-halogen bond of 2-iodobenzoid acid was selected.  
This approach used an inexpensive commercially available starting material and used a 
reasonable electron flow from the electron rich aniline into the electron deficient 2-iodo 
benzoic acid.   An Ullmann coupling strategy worked to give the desired acid in a 44% 
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isolated yield.  A survey recent variations110 recommended the conditions that were 
ultimately selected and shown in scheme 26.  The specific method employed used copper 
iodide, potassium carbonate, and a mixed solvent system of 9 to 1 DMF to water.  
Efficient heating was provided by microwave irradiation.  
 
Scheme 26: Ullmann coupling strategy to synthesize 25. 
In case of the unhalogenated diphenylamine, compound 25, a different amide-forming 
strategy was required. The acid chloride method described previously did not work.  
Probable reasons for the failure of this strategy include the increased nucleophilicity of 
the amine of compound 25 resulting from the absence of electron-withdrawing groups 
compared to compounds previously synthesized in the series described above.  This 
greater electron density in compound 95 may have led to self-condensations in either 
inter- or an intra- molecular manner.  This explanation is consistent with the observed 
consumption of starting material with no isolable product. 
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Scheme 27: The acid chloride method for the synthesis of amide 75. 
The next approach attempted for the synthesis of compound 75 was synthesis of the Boc-
piperazine derivative 96 followed conversion to the piperazine analog.  Synthesis to the 
tertiary amine using an Eschweiler-Clarke reaction was planned. However, the 
Eschweiler-Clarke product could not be isolated (Scheme 28).  Learning from prior 
reactions, this strategy was abandoned for the far more efficient route (DIC coupling) 
presented in Scheme 29. 
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Scheme 28: Synthesis of 75 via Eschweiler-Clarke reaction. 
This DIC coupling was successful and the product was isolated in a modest yet welcome 
17% yield.111  
 
Scheme 29: DIC coupling method to synthesize 75. 
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An attempted SNAr nucleophilic of the lithium amid of 2-fluoro-4-iodoanaline into 2-
iodobenzoic acid with excess lithium amide in THF using the now standard procedure of 
Davis85 was unsuccessful. This was probably due to a more electropositive carbon at the 
2 position when compared to the prior substrate, 2,3,4-trifluorobenzoic acid.  Again, 
based on prior observations, alteration of the synthetic strategy to use an Ullmann 
coupling was shown to be successful and proceeded reliably in 40 – 60 % isolated then 
recrystallized yield. 
 
 
Scheme 30: Synthesis of amides 75 and 74. 
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Synthesis of the N-methyl diphenylamine core: 
An Eschweiler-Clarke reaction112 was examined as an initial strategy in an attempt to 
prepare 3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid, compound 
76.  The use of standard microwave reaction conditions were examined, but the desired 
product could not be isolated.   
  
Scheme 31: Eschweiler-Clarke strategy to synthesize 76. 
 
 
Scheme 32:  Mechanism of Eschweiler-Clarke reaction. 
An explanation for the failure of the Eschweiler-Clarke reaction likely arises from 
difficulty when forming the “iminium ion” (104).  For the initial step -shown above- 
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nucleophilic attack by the significantly electron deficient nitrogen atom into the molecule 
of formaldehyde would be difficult and slow and could hinder or halt the reaction. 
 
Another strategy was attempted using sodium hydride abstraction of the proton from the 
diphenyl amine nitrogen atom followed by alkylation with methyl iodide (Scheme 33).113  
A crude TLC analysis revealed many spots, attempted separation by column 
chromatography was unsuccessful. 
 
Scheme 33: Synthesis of 76 by sodium hydride and methyl iodide reaction. 
After the two unsuccessful synthetic approaches a very different strategy was pursued.  
Alkylation was conducted on the simple aniline precursor, 2-fluoro-4-iodoaniline 38, to 
successfully prepare the mono N-methylated product, 2-fluoro-4-iodo-N-methylaniline 
108, shown in scheme 34.114  This secondary aniline was then coupled to 2,3,4-
trifluorobenzoic acid (37) using the standard SNAr lithium amide displacement 
approach.85 
 
Scheme 34: Monomethylation reaction of 38. 
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Scheme 35: Synthesis of acid 76 by lithium amide displacement method. 
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Chapter 5 
 
Biological discussion 
 
There has been extensive prior SAR conducted on what makes a potent Type III MEK1 
inhibitor.61, 115  A summary of known SAR for MEK1 overlaid on PD 325901, compound 
5, is shown below in figure 39.  
 
Figure 40: MEK1/2 interaction with inhibitor PD325901.115 
Terminal B ring forms Van der Waals interactions with the hydrophobic pocket formed 
by Met143, Ile141, Leu118, and Phe209.  Phe209 has been proposed to form an 
important edge-to-face aromatic interaction with the B ring. 
A significant determinant MEK1 activity, both in the literature and also in our testing, is 
the essential presence of an electrostatic interaction, or halogen interaction between the 
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lone pair of electrons on the oxygen atom of the backbone carbonyl of Val127 and the 4′-
iodide on the B ring.67 
A second significant determinant MEK1 activity is the hydrogen bond interaction, 
between the 4-fluoro atom of the central A ring and the backbone amide of Ser212.  
 
Our aim was to rationally design toward MEK5 selectivity and analyze the observed 
differences in activity on the basis of MEK5 interactions proposed on the basis of the 
homology model.  A rigorous SAR in the absence of a direct enzymatic assay is 
inappropriate, but the cellular model is likely to be more descriptive of an intact 
biological cascade. 
 
1. Side chain variation and amide variation:  
 
All amide variations were conducted on the tetra-halogenated ring system.  The 
rationale for this approach was based in part on the synthetic approach that 
permitted these point variations from a common synthetic intermediate.  However 
this approach permitted better comparison as a single component was altered to 
provide a better basis for rational interpretation.  These compounds showed potent 
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MEK1/2 inhibition.  This is not surprising as these compounds retained the 
major/critical MEK1/2 interactions.  It was hoped on the basis of the homology 
model that differential activity would be observed but this was not seen. The 
primary amide (57) was found to be a non-selective MEK1 and MEK5 inhibitor. 
2. Terminal arene variation: 
 
Compounds without fluorine on the central A ring yet retaining the 2-F-4-I atoms 
on the B ring showed improved MEK5 inhibition plus showed reduced MEK1/2 
inhibition.  The decrease in MEK1 inhibition was most likely due to the loss of 
the hydrogen bond interaction of the 4-fluoro from the A ring to the amide 
backbone of Ser212 (Figure 39).  This is not well predicted by the homology 
model, but as indicated in analysis in the appendix, this is a region of greater 
variability between MEK1 and MEK5.  Additionally this alpha helix is known to 
move relative to the anti-parallel beta sheets comprising the N-terminal domain of 
the catalytic (ATP binding) domain of the enzyme and the alpha helix is likely to 
rotate or roll to expose a different surface to the type III binding site.  An X-ray 
crystal structure could partially address these variations. 
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3. Central arene variation: 
 
The compound 72 with 2 fluorine atoms in the central A ring and the complete 
absence of halogens on the B ring showed the maximum MEK5 inhibition 
amongst all the other variations examined.  Also, this compound did not show any 
MEK1 inhibition in the cellular assay.  The full absence of observed activity for 
MEK1 is unsurprising.  From a structural perspective the electrostatic (halogen) 
interaction is consistently present in all MEK1 or MEK2 X-ray crystallographic 
structures deposited in the PDB.  From a medicinal chemistry perspective all 
potent MEK1 inhibitors in the literature, including the approved MEK1 inhibiting 
drug Mekinist, rigorously retain this interaction.  The homology model does 
predict that this region is smaller in MEK5.  It was anticipated that a modest 
decrease in MEK1 activity would be observed and any selectivity would result 
from less than ideal water displacement from the B ring binding site. 
4. Target compounds with de-iodo diphenylamine: 
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The de-iodo acid 68 did not display any MEK5 inhibition and showed only 30% 
MEK1 inhibition in the cellular assay.  This observation was consistent with the 
proposed importance of the 4′-I halogen bond as being essential to MEK1 
inhibition activity.  However, its N-methyl piperazine 69 analog displayed an 
increased MEK5 inhibition with up to 56% inhibition being observed while 
retaining the lower 30% MEK1 inhibition of its de-iodo structural variation, 
compound 68.  This suggests that additional variation of the amide portion 
following aromatic ring variation may result in compounds with equally increased 
MEK5 activity as well. 
 
5. Target compounds with no halogens on rings A and B: 
 
The compound with no halogens on either of the rings was expected to lose at 
least two major MEK1 interactions, however it still displayed 30% MEK1 
inhibition.  It also inhibited MEK5 up to 71%.  Possible explanations include that 
halogen and hydrogen bonding interactions are additive to other portions of the 
molecule if the minimum structural requirements of an amide and two 
hydrophobic regions are present.  The homology model also suggests that 
variation on the B ring may be useful due to proposed structural variation of the 
homology model of MEK5DD from the structure of MEK1 presented by 3EQC.  
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Compound 75 anticipates that central A ring substitution may not be necessary.  
In the case of MEK1 inhibitors, as discussed previously, this was a design 
strategy for A-ring variations which was successfully used to ultimately design 
the drug Mekinist. 
 
6. Variations on the nitrogen atom of the diphenylamine: 
 
The N-methyl compound 76 was a very important compound in our series to 
establish the relevance of the internal hydrogen bond. The N-methyl compound 
displayed only 18% MEK5 inhibition, but still showed 67% MEK1 inhibition. It 
was anticipated that a parallel decrease in both MEK1 and MEK2 activity would 
be observed because the majority of MEK1 inhibitors in the PDB display internal 
hydrogen bonding. Because the homology model was based on MEK1 it was 
anticipated that this would apply to MEK5 as well.  Apparently this is not the 
case.  Conducting the assays concurrently in the same cell population provides an 
important internal control and retention of MEK1 inhibition suggests that the 
observed loss of MEK5 activity is unlikely to arise from inadequate transport into 
the cell.  Thus we are examining the geometry imposed by the internal hydrogen 
bonding as a design strategy to differentiate structural requirements for type III 
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MEK5 inhibitors versus type III MEK1 inhibitors and synthesizing ring-
constrained diphenylamine analogs to explore this unanticipated finding. 
 
Compounds pERK5 
activation (%) 
pERK5 
inhibition (%) 
pERK1/2 
activation (%) 
pERK1/2 
inhibition (%) 
DMSO 100 0 100 0 
64 (SC-1-75) -- 8.4 -- 70.9 
59 (SC-1-65) 7.4 -- -- 5.5 
74 (SC-1-24) -- 30.9 -- 33.5 
65 (SC-1-122) -- 9.4 -- 27.9 
58 (SC-1-69) -- 0.2 -- 87.3 
60 (SC-1-72 a) -- 20.4 -- 99.6 
62 (SC-1-72 e) -- 13.0 -- 98.9 
63 (SC-1-79) 6.2 -- -- 99.0 
61 (SC-1-80) -- 8.5 -- 98.6 
75 (SC-1-177) -- 71 -- 29.3 
72 (SC-1-181) -- 82.4 8.5 -- 
57 (SC-1-151) -- 59 -- 96.8 
39 (SC-1-180) -- 20.1 -- 98.5 
71 (SC-1-175) -- 10.4 -- 7.1 
68 (SC-2-25) -- 11.1 7.1 -- 
76 (SC-2-32) 5.5 -- -- 33.5 
70 (SC-2-37) -- 56.1 -- 52.8 
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69 (SC-2-45) -- 40.5 -- 16.5 
U0126 -- 43 -- 99.6 
XMD8-92 -- 95.2 -- 50.1 
PD 0325901 -- 95.9 -- 99.7 
 
Table 12: MEK1/2 and MEK5 inhibition data. 
Our collaborator Dr. Matthew Burow in Tulane University, New Orleans further tested 
the compounds in proliferation and cell viability assays in MDA-MB-231 cells.  The 
normal duration of this study was 24 hrs to 3 days, however, a temporary closure of the 
lab for a week, led to the discovery of a morphological change in the shape of the cells.  
The treatment of MDA-MB-231cells presented an MET (mesenchymal to epithelial 
transition) when exposed to a concentration of 10 M of compound for a 7-day interval.  
This unexpected finding suggests the potential for MEK inhibitors to facilitate an MET in 
vitro breast cancer cells grown in charcoal-stripped media. 
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Chapter 6 
 
Experimental 
 
All solvents and reagents were used as received unless noted otherwise.  All reactions 
were conducted in dry glassware and under an atmosphere of argon unless otherwise 
noted.  Microwave reactions were conducted in sealed tube and utilized a multimode 
Milestone Start apparatus for irradiation with power and control parameters as noted. 
Melting points were determined on a MelTemp apparatus and are uncorrected.  All 
proton NMR spectra were obtained with a 500 MHz or a 400 MHz Oxford spectrospin 
cryostat, controlled by a Bruker Avance system, and were acquired using Bruker 
TOPSPIN 2.0 acquisition software. Acquired FIDs were analyzed using MestReC 3.2. 
Elemental analyses were conducted by Atlantic Microlabs and are ± 0.4 of theoretical. 
All 1H NMR spectra were taken in CDCl3 unless otherwise noted and are reported as ppm 
relative to TMS as an internal standard. Coupling values are reported in Hertz.  All TLCs 
were obtained on Sorbent Technologies polyester backed Silica G TLC Plates of 
thickness 200 µm. 
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General Method A:  
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (SC-1-180) (39).  A 250 
mL round bottom flask was charged with 2-fluoro-4-iodoaniline, (38; 2.38 g, 10.0 mmol), 
2,3,4-trifluorobenzoic acid, (37; 1.80 g, 10.2 mmol), and 30 mL of anhydrous THF. The 
reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (561.2 mg, 24.45 mmol) 
was added in 3 portions over 10 min.  The reaction was then warmed to an internal 
temperature of 58 oC and stirred for 12 h. The mixture was cooled to 0 oC and 1 N HCl 
was added maintaining the reaction mixture at 0 oC to yield a final pH of 1.0 (red to 
pHydrion paper). The reaction mixture was then extracted three times with 10 mL 
portions of Et2O, washed three times with 5 mL portions of 1 N HCl, washed with NaCl 
(aq, sat), and dried over Na2SO4. The extract was decanted and the solvent was removed 
under reduced pressure. The crude product was isolated on SiO2 using 2:1 hexane/EA to 
provide 2.11 g (53%) of a white solid.  MP = 199.0 - 200.1 oC (lit. MP = 200 - 201 oC).85  
SiO2 TLC Rf  0.51 (2:1 hexane/EA).  
1H NMR (400 MHz, MeOD-d4): δ 6.74 (m, 1 H, 
Ar), 6.91 (m, 1 H, Ar), 7.38-7.45 (d, 1 H, J = 8.5 Hz, Ar), 7.47 (dd, 1H, J1 = 1.8 Hz and 
J2 = 10.5 Hz, Ar), 7.89 (br, 1 H, Ar). Anal Calcd for C13H7F3INO2: C, 39.72; H, 1.79; N, 
3.56. Found: C, 39.41; H, 1.91; N, 3.52. 
 
General procedure B: Acid chloride approach to synthesize amide: 
A dry 100 mL round bottomed flask was charged with 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (39) and 5 mL of DCM. The reaction mixture was 
cooled with an ice-bath to 0 oC. 100 μL of anhydrous DMF was added followed by 
dropwise addition of neat oxalyl chloride (2 equiv.) over 5 min.  The reaction was stirred 
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at 23 oC for 4 h. The solvent was then removed under reduced pressure. Excess oxalyl 
chloride was azeotropically removed with 2 X 5 mL portions of DCM under reduced 
pressure. The crude product was dissolved into 5 mL of DCM and the appropriate amine 
was added neat at 0 oC. The ice bath was removed after 10 min and the reaction was 
permitted to warm to room temperature. The reaction was then stirred at 23 oC for 6 h; 
completion of reaction was determined by TLC. A mixture of 10 mL of H2O and 10 mL 
of Et2O was added and the resultant mixture was extracted with Et2O, washed with NaCl 
(aq, sat), and dried over Na2SO4. The extract was decanted and then the solvent was 
removed under reduced pressure. The crude product was isolated on SiO2 using 
hexane/EA. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-151) (57):  was 
synthesized using procedure B from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (39; 1.2 g, 3.0 mmol) and 7 N NH3 in methanol (2 mL, 
15.73 mmol). The crude product was isolated on SiO2 using 2:1 hexane/EA to give 900 
mg (73%) of a pink-white powder. MP = 160.9 – 162.0 oC. SiO2 TLC Rf 0.29 (2:1 
hexane/EA). 1H NMR (400 MHz, CDCl3): δ 5.72-6.22 (br. d, 2 H, NH2), 6.60-6.64 (m, 1 
H, NH), 6.85-6.90 (m, 1 H, Ar), 7.34 (d, 1 H, J = 8.5 Hz, Ar), 7.39-7.43 (m, 2 H, Ar), 
8.71 (s, 1 H, Ar). Anal Calcd for C13H8F3IN2O: C, 39.82; H, 2.06; N, 7.14. Found: C, 
39.86; H, 2.18; N, 7.24. 
 
N,N-diethyl-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-65) (59):  
Compound 59 was synthesized using procedure B (acid chloride approach) from 3,4-
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difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (39; 200 mg, 0.51 mmol) and 
diethyl amine (0.16 mL, 1.53 mmol). The crude product was isolated on SiO2 using 1:1 
hexane/EA and recrystallised from hexanes to give 100.2 mg (45%) of a white solid. MP 
= 78.9 – 80.1 oC. SiO2 TLC Rf 0.7 (1:1 hexane/EA). 1H NMR (400 MHz, CDCl3): δ 1.07 
(br, 6 H), 3.22-3.46 (br. d, 4 H, 2N-CH2), 6.50 (s, 1 H, NH) 6.51-6.55 (m, 1 H, Ar), 6.9-
7.04 (m, 2 H, Ar), 7.27-7.29 (d, 1 H, J = 8.5 Hz, Ar), 7.34-7.37 (dd, 1 H, J1 =  1.9 Hz and 
J2 = 10.5 Hz, Ar). Anal Calcd for C17H16F3IN2O: C, 45.5; H, 3.60; N, 6.25; F, 12.72; I, 
28.31. Found: C, 45.25; H, 3.57; N, 6.25; F, 12.86; I, 28.22. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N,N-dimethylbenzamide (SC-1-69) 
(58):  Compound 58 was synthesized using procedure B from 3,4-difluoro-2-((2-fluoro-
4-iodophenyl)amino)benzoic acid, (39; 200.0 mg, 0.51 mmol) and dimethyl amine HCl 
(408 mg, 5.0 mmol). A solution of dimethyl amine HCl in 5 mL H2O was added with 
dropwise addition to a suspension of Na2CO3 (7 mmol), H2O (5 mL), DCM (25 mL), and 
DMAP (5.0 mg, 0.04 mmol) at 0 oC. The solution of acid chloride in DCM was added 
over 5 min and the reaction was stirred at 23 oC for 2 h. A mixture of 10 mL of H2O and 
50 mL of DCM was added and the resultant mixture was washed with H2O (2 X 10 mL), 
washed with NaCl (aq, sat), and then dried over Na2SO4. The crude product was isolated 
on SiO2 using 2:1 hexane/EA to give 47 mg (22%) of a white solid. MP = 115.4 – 117.7 
oC. SiO2 TLC Rf 0.61 (2:1 hexane/EA). 
1H NMR (400 MHz, CDCl3): δ 2.96 (br, 3 H, 
CH3), 2.91 (br, 3 H, CH3), 6.53-6.59 (m, 1 H, Ar), 6.82 (s, 1 H, NH), 6.91-6.95 (m, 1H, 
Ar), 7.02-7.06 (m, 1 H, Ar), 7.29-7.31 (d, 1 H, J = 8.5 Hz, Ar), 7.36-7.39 (dd, 1 H, J1 = 
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1.9 Hz and J2 = 10.4 Hz, Ar). Anal Calcd for C15H12F3IN2O: C, 42.8; H, 2.8; N, 6.67; F, 
13.5; I, 30.2. Found: C, 42.69; H, 2.89; N, 6.53; F, 13.45; I, 29.99. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-methylbenzamide (SC-1-72 amide) 
(60): was synthesized using procedure B from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (39; 315 mg, 0.8 mmol) and methylamine in methanol 
(0.5 mL, 4 mmol, 8 M solution). The crude product was isolated on SiO2 using 5:1 
hexane/EA and recrystallized from hot EtOH to give 203 mg (63%) of a white solid. MP 
= 159.0 – 160.2 oC. SiO2 TLC Rf 0.51 (1:1 hexane/EA). 1H NMR (500 MHz, CDCl3): δ 
2.95 (d, 3 H, J = 4.8 Hz), 6.23 (br, 1 H, NH), 6.54-6.59 (m, 1 H, Ar), 6.82-6.88 (m, 1 H, 
Ar), 7.28-7.32 (m, 2 H, Ar), 7.40 (dd, 1 H, J = 1.9 Hz and J = 10.3 Hz, Ar), 8.61 (s, 1 H, 
NH). Anal Calcd for C14H10F3IN2O: C, 41.40; H, 2.48; N, 6.90; F, 14.03; I, 31.25. Found: 
C, 41.67; H, 2.51; N, 6.79; F, 13.79; I, 31.35. 
 
Methyl 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoate (SC-1-72 ester) (62): 
was obtained as a side-product using procedure B during the synthesis of 60 from 3,4-
difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (39; 315 mg, 0.8 mmol) and 
methylamine in methanol (0.5 mL, 4 mmol, 8 M solution). The product was obtained as 
60 mg (17%) of a white solid. MP = 118.5 – 111.4 oC. SiO2 TLC Rf 0.82 (2:1 
hexane/EA). 1H NMR (400 MHz, CDCl3): δ 3.91 (s, 3 H), 6.65-6.71 (m, 1 H, Ar), 6.74-
6.80 (m, 1 H, Ar), 7.35 (d, 1 H, J = 8.6 Hz), 7.42 (dd, 1 H, J = 1.9 Hz and J = 10.2 Hz, 
Ar), 7.78-7.82 (m, 1 H, Ar), 9.04 (s, 1 H, NH). Anal Calcd for C14H9F3INO2: C, 41.30; H, 
2.23; N, 3.44; F, 14.00; I, 31.17. Found: C, 41.43; H, 2.08; N, 3.52; F, 14.18; I, 31.31. 
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Tert-butyl 4-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)piperazine-1-
carboxylate (SC-1-75) (64):  Compound 64 was synthesized using procedure B from 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (39; 1.00 g, 2.54 mmol) and 
N-Boc-piperazine (2.85 g, 5.08 mmol). A solution of acid chloride in 6 mL DCM was 
added with dropwise addition to a solution of N-Boc-piperazine, TEA (0.70 mL, 5.08 
mmol), DCM (12 mL) and DMAP (5.0 mg, 0.04 mmol) at 0 oC and the reaction was 
stirred at 23 oC for 2 h. The crude product was isolated on SiO2 using 2:1 hexane/EA to 
give 630 mg (44%) of a white solid. MP = 188.4 oC. SiO2 TLC Rf 0.5 (1:1 hexane/EA). 
1H NMR (400 MHz, CDCl3): δ 1.45 (s, 9 H), 3.34-3.55 (m, 8 H), 6.53-6.58 (m, 1 H, Ar), 
6.62 (s, 1 H, NH), 6.92-6.96 (m, 1 H, Ar), 7.03 (m, 1 H, Ar), 7.30 (d, 1 H, J = 8.9 Hz, 
Ar), 7.39 (dd, 1 H, J = 1.9 Hz and J = 10.4 Hz, Ar). Anal Calcd for C22H23F3IN3O3: C, 
47.07; H, 4.13; N, 7.49; F, 10.15; I, 22.61. Found: C, 47.22; H, 4.18; N, 7.40; F, 9.94; I, 
22.64. 
 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(piperazin-1-yl)methanone 
hydrochloride (SC-1-79) (63):  was synthesized from 64 (530 mg, 0.94 mmol) and 1:1 
15 mL (v/v) HCl/Dioxane. A solution of 64 was taken in a 250 mL RBF and 15 mL of 
1:1 conc. HCl in Dioxane was added with constant stirring at 23 oC for 3.5 hrs. The crude 
product was recrystallized from hot EtOH to give 340 mg (79%) of a white solid; MP = 
201.2 – 203.6 oC. 1H NMR (400 MHz, MeOD-d4): δ 3.08 (br, 4 H), 3.60 (m, 4 H), 6.58-
6.62 (t, 1 H, Ar), 7.12-7.22 (m, 2 H, Ar), 7.32 (d, 1 H, J = 8.5 Hz, Ar) 7.46 (dd, 1 H, J = 
1.9 Hz and J = 10.8 Hz, Ar). Anal Calcd for C17H15F3IN3O: C, 41.03; H, 3.24; N, 8.44; F, 
11.45; I, 25.50. Found: C, 40.77; H, 3.38; N, 8.34; F, 11.20; I, 25.24. 
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N-ethyl-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-80) (61):  
was synthesized using procedure B from 3,4-difluoro-2-((2-fluoro-4-
iodophenyl)amino)benzoic acid, (39; 315 mg, 0.8 mmol) and ethyl amine 2M solution in 
THF (2.25 mL, 4.5 mmol). The crude product was isolated on SiO2 using 2:1 hexane/EA 
and recrystallized from hot EtOH to give 155 mg (41%) of a white solid. MP = 172.5 – 
173.6 oC. SiO2 TLC Rf 0.7 (2:1 hexane/EA). 
1H NMR (400 MHz, CDCl3): δ 1.19 (t, 3 H, 
J = 7.3 Hz), 3.38-3.45 (m, 2 H), 6.22 (br, 1 H, NH), 6.54-6.59 (m, 1 H, Ar), 6.82-6.89 (m, 
1 H, Ar), 7.31 (m, 2 H, Ar), 7.40 (dd, 1 H, J = 2.0 Hz, J = 10.3 Hz, Ar), 8.52 (s, 1 H, 
NH). Anal Calcd for C15H12F3IN2O: C, 42.88; H, 2.88; N, 6.67; F, 13.56; I, 30.20. Found: 
C, 42.89; H, 2.89; N, 6.60; F, 13.57; I, 30.47. 
 
N-(2-(dimethylamino)ethyl)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-
methylbenzamide hydrochloride (SC-1-122) (65):  was synthesized using procedure B 
from 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid, (39; 360 mg, 0.88 
mmol) and N,N,N’-trimethylethane-1,2-diamine (0.34 ml, 2.64 mmol). A solution of 
N,N,N’-trimethylethane-1,2-diamine (0.34 ml, 2.64 mmol), TEA (0.37 mL, 2.64 mmol) 
and DMAP (6 mg, 0.05 mmol) in 3 mL DCM was added dropwise to a solution of the 
acid chloride in DCM over 5 min and the reaction was stirred at 23 oC for 12 h. The crude 
product was isolated on SiO2 using CHCl3 and 5% MeOH to give 290 mg. HCl salt was 
made from ethereal HCl and recrystallized from hot ethanol to afford 168.2 mg (40%) of 
a white solid. MP = 211 – 213 oC. SiO2 TLC Rf 0.7 (DCM/ 5% MeOH/ 0.1% NH4OH). 
1H NMR (500 MHz, DMSO-d6) : δ  2.78 (s, 6 H, 2CH3), 2.84 (s, 3 H, CH3), 3.13 (m, 2 H, 
CH2), 3.61 (t, 2 H, CH2), 6.59-6.63 (t, 1 H, Ar), 7.27-7.33 (m, 2 H, Ar), 7.52-7.53 (dd, 1 
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H, J = 1.6 Hz, J = 11.3 Hz, Ar), 8.05 (s, 1 H, Ar), 10.06 (s, 1 H, NH). Anal Calcd for 
C18H20ClF3IN3O: C, 42.08; H, 3.92; N, 8.18; F, 11.09; I, 24.70. Found: C, 42.21; H, 3.98; 
N, 8.09; F, 11.22; I, 24.52. 
 
Procedure C (Ullmann coupling): 
2-((2-fluoro-4-iodophenyl)amino)benzoic acid (SC-1-14) (98): A microwave reactor 
tube was charged with ortho-iodo benzoic acid (496 mg, 2 mmol), 2-fluoro-4-iodo aniline 
(237 mg, 1 mmol), K2CO3 (416 mg, 3 mmol), CuI (200 mg, 1.04 mmol) and 5 mL 
DMF/H2O (9:1). The reaction was subjected to 300 Watt microwave irradiation with the 
internal temperature maintained at 100 oC for 2 h. After completion of the reaction was 
analyzed by TLC, 1 N HCl (~ 4 mL) was added to the reaction mixture to obtain a final 
solution pH of 6.0. The solvent was then removed under reduced pressure. The crude 
compound was isolated on SiO2 using 1:1 hexane/EA to give 217 mg (61%) of white 
solid; MP = 186.2 – 186.5 oC. SiO2 TLC Rf 0.70 (1:1 hexane/EA). 1H NMR (400 MHz, 
CDCl3): δ 6.85 (t, 1 H, J = 7.1 Hz, Ar), 7.11 (d, 1 H, J = 8.6 Hz, Ar), 7.20 (t, 1 H, J = 8.4 
Hz, Ar), 7.42 (m, 2 H, Ar), 7.50 (dd, 1 H, J = 2.0 Hz and J = 9.8 Hz, Ar), 8.06 (dd, 1 H, J 
= 1.6 Hz and J = 8.1 Hz, Ar), 9.25 (s, 1 H, CO2H). Anal Calcd for C13H9FINO2: C, 43.72; 
H, 2.54; N, 3.92. Found: C, 43.81; H, 2.65; N, 3.80. 
 
(2-((2-fluoro-4-iodophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
hydrochloride (SC-1-24) (74): A dry 100 mL round bottom flask was charged with 98, 
(140 mg, 0.39 mmol) and 5 mL of DCM.  The reaction mixture was cooled on ice-bath to 
0 oC. 100 μL of anhydrous DMF was added followed by dropwise addition of oxalyl 
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chloride (70 μL, 0.8 mmol) over 2 min at 0 oC.  The reaction was stirred at 23 oC for 2 h. 
The solvent was then removed under reduced pressure.  The crude product was dissolved 
into 5 mL of DCM and N-methyl piperazine (0.5 mL, 4.5 mmol) was added neat at 23 oC.  
The reaction was stirred at 23 oC for 2 h; completion of reaction was determined by TLC.  
A mixture of 10 mL of DCM and 5 mL of 5% Na2CO3 was added and the resultant 
mixture was extracted with DCM, washed with NaCl (aq, sat), and dried over Na2SO4. 
The extract was decanted and then the solvent was removed under reduced pressure and 
water chased with toluene. The crude product was isolated on SiO2 using EA/0.5% 
TEA/10% ethanol and recrystallised from HCl salt (ethereal HCl) to give 20 mg (12%) of 
off-white powder. MP = 217.2 – 217.5 oC. SiO2 TLC Rf 0.24 (20% EA/EtOH). 1H NMR 
(400 MHz, MeOD-d4): δ 1.18 (t, 4 H, J = 7.0 Hz), 2.89 (s, 3 H), 3.49 (q, 2 H, J = 7.0 Hz), 
3.60 (q, 2 H, J = 7.1 Hz), 6.92 (t, 1 H, J = 8.7 Hz), 7.09 (t, 1 H, J = 7.5 Hz), 7.15 (d, 1 H, 
J = 8.2 Hz), 7.34-7.42 (m, 3 H), 7.49 (dd, 1 H, J = 2.0 Hz and J = 10.7 Hz). Anal Calcd 
for C18H20ClFIN3O. 0.38 % EtOH: C, 45.68; H, 4.55; N, 8.51; F, 3.85; I, 25.71; Cl, 7.18. 
Found: C, 45.9; H, 4.49; N, 8.54; F, 3.66; I, 25.68; Cl, 7.49. 
 
2-(phenylamino)benzoic acid (SC-1-39) (25):  A microwave reactor tube was charged 
with ortho-iodo benzoic acid (496 mg, 2 mmol), aniline (24) (0.45 mL, 4 mmol), K2CO3 
(832 mg, 6 mmol), CuI (400 mg, 2.08 mmol) and 10 mL DMF/H2O (9:1). The reaction 
was subjected to 300 Watt microwave irradiation with the internal temperature 
maintained at 100 oC for 1 h.  After completion of the reaction was observed by TLC, 1 N 
HCl (~ 9 mL) was added to the reaction mixture to obtain a final pH of 6.0. The solvent 
was then removed under reduced pressure and water was azeotropically removed with 3 
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X 10 mL of toluene.  The crude compound was isolated on SiO2 using hexane/EA and 
recrystallised from toluene to give 267 mg (63%) of white solid; MP = 176.6 – 177.0 oC. 
1H NMR (400 MHz, CDCl3): δ 6.76 (t, 1 H, J = 7.5 Hz, Ar), 7.13 (t, 1 H, J = 7.3 Hz, Ar), 
7.23 (d, 1 H, J = 8.7 Hz, Ar), 7.26-7.28 (m, 2 H, Ar), 7.33-7.39 (m, 3 H, Ar), 8.04 (dd, 1 
H, J = 1.6 Hz and J = 8.1 Hz, Ar), 9.33 (s, 1 H, CO2H). 
 
Procedure D (DIC coupling) 
(4-methylpiperazin-1-yl)(2-(phenylamino)phenyl)methanone (SC-1-177 amide) (75): 
A dry 100 mL round bottom flask was charged with 25, (1.00 g, 4.69 mmol) and 12 mL 
of DCM.  N-methyl piperazine (2.59 mL, 23.45 mmol) and DMAP (9 mg, 0.07 mmol) 
was added followed by DIC (1.08 mL, 7 mmol) and the reaction mixture was stirred at 23 
oC for 22 h. The solvent was removed under reduced pressure. A mixture of 10 mL of 
ether and HCl was added and the resultant mixture was extracted into HCl (3 X 5 mL) 
and washed with ether (2 X 5 mL). The aqueous layer was basified with 5% Na2CO3 and 
the crude material was extracted into DCM (3 X 8 mL). The crude product was loaded 
onto SiO2 and eluted with chloroform: methanol (95:5). Collection of appropriate 
fractions, removal of solvent, and recrystallization from hot ethanol gave 232 mg (17%) 
of transparent colorless needles. MP = 105.9 – 108.0 oC. SiO2 TLC Rf 0.35 (chloroform/ 
1% methanol). 1H NMR (400 MHz, MeOD-d4): δ 2.23 (s, 3 H, CH3), 2.35 (br, 4 H, 
2CH2), 3.73-3.82 (m, 4 H, 2CH2), 6.88 (t, 1 H, J = 7.3 Hz), 6.97-7.01 (m, 3 H, Ar), 7.19-
7.26 (m, 4 H, Ar), 7.30-7.34 (m, 1 H, Ar). Anal Calcd for C18H21N3O: C, 73.19; H, 7.17; 
N, 14.23. Found: C, 73.14; H, 7.22; N, 14.23. 
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3,4-difluoro-2-(phenylamino)benzoic acid (SC-1-175 acid) (71): A 250 mL round 
bottom flask was charged with aniline (24) (0.57 mL, 5.7 mmol), 2,3,4-trifluorobenzoic 
acid (37), (1 g, 5.7 mmol), and 15 mL of anhydrous THF. The reaction mixture was 
cooled with an ice-bath to 0 oC and LiNH2 (327 mg, 14.25 mmol) was added in portions 
2 portions over 10 min.  The reaction was then warmed to 58 oC (external temperature) 
and stirred for 7 h.  1 N HCl was then added to the reaction mixture at 0 oC to obtain a 
final pH of 1.0 (red to pHydrion paper). The reaction mixture was extracted three times 
with 5 mL portions of Et2O, washed three times with 5 mL portions of 1 N HCl, washed 
with NaCl (aq, sat) and dried over Na2SO4.  The extract was decanted and the solvent was 
removed under reduced pressure. The crude product was isolated on SiO2 using 
hexane/EA and provided 606 mg (44 %) yellow crystals.  MP = 162.1 – 162.6 oC.  SiO2 
TLC Rf  0.61 (2:1 hexane/EA).
 1H NMR (500 MHz, CDCl3): δ 6.73-6.78 (m, 1 H, Ar), 
7.05 (d, 2 H, J = 7.5 Hz, Ar), 7.10 (t, 1 H, J = 7.4 Hz), 7.32 (t, 2 H, J = 7.6 Hz), 7.87-7.90 
(m, 1 H, Ar), 8.99 (s, 1 H, OH). 
 
Procedure E (EDCI coupling) 
3,4-difluoro-2-(phenylamino)phenyl)(4-methylpiperazin-1-yl)methanone (SC-1-181) 
(72):  A solution of 71 (249 mg, 1 mmol), N-methyl piperazine (0.25 mL, 2 mmol) and 
DMAP (6 mg, 0.05 mmol) was prepared in 10 mL anhydrous THF, then EDCI (382 mg, 
2 mmol) was added in one portion. The reaction mixture was stirred at 23 oC for 12 hrs. 
The solvent was removed under reduced pressure and a mixture of 50 mL of ether and 1 
mL H2O was added. The resultant mixture was washed three times with 1mL portions of 
H2O, 5 mL of saturated NaCl and then dried over anhydrous Na2SO4. The crude product 
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was isolated on SiO2 using CHCl3, 1% MeOH, 1% TEA to give 204 mg (62%) of a white 
solid. MP = 153.0 – 155.3 oC. 1H NMR (400 MHz, CDCl3): δ 2.22 (s, 4 H, 2CH2), 2.27 
(br, 3 H, CH3), 3.47 (br, 4 H, 2CH2), 6.60 (s, 1 H, NH), 6.82-6.95 (m, 4 H, Ar), 6.99-7.03 
(m, 1 H, Ar), 7.22-7.24 (m, 2 H, Ar). Anal Calcd for C18H19F2N3O: C, 65.24; H, 5.78; N, 
12.68; F, 11.47. Found: C, 65.38; H, 5.89; N, 12.72; F, 11.46. 
 
3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid (SC-2-25 acid) (68): A 100 mL 
dry round bottom flask was charged with 2-fluoroaniline (0.27 mL, 2.97 mmol), 2,3,4-
trifluorobenzoic acid, (528 mg, 3 mmol), and 7 mL of anhydrous THF. The reaction 
mixture was cooled with an ice-bath to 0 oC and LiNH2 (165.2 mg, 7.2 mmol) was added 
in 2 portions over a 10 min interval.  The reaction was then warmed to 58 oC (external 
temperature) and stirred for 4 h.  1 N HCl was then added to the reaction mixture at 0 oC 
to obtain a final pH of 1.0 (red to pHydrion paper). The reaction mixture was extracted 
three times with 5 mL portions of Et2O, washed three times with 5 mL portions of 1 N 
HCl, washed with NaCl (aq, sat), and dried over Na2SO4.  The extract was decanted and 
the solvent was removed under reduced pressure. The crude product was isolated on SiO2 
using hexane/EA to provide 471 mg (59 %) of white crystals.  MP = 170 – 172 oC.  SiO2 
TLC Rf  0.55 (2:1 hexane/EA). 
1H NMR (400 MHz, CDCl3): δ 6.72-6.78 (dt, 1 H, J = 6.8 
Hz and J = 9.1 Hz, Ar), 7.00-7.13 (m, 4 H, Ar), 7.87-7.91 (ddd, 1 H, J = 2.1 Hz, J = 5.8 
Hz and J = 9.1 Hz, Ar), 8.92 (s, 1 H, CO2H). Anal Calcd for C13H8F3NO2: C, 58.44; H, 
3.02; N, 5.24. Found: C, 58.41; H, 3.02; N, 5.23. 
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(3,4-difluoro-2-((2-fluorophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
mono-fumarate (SC-2-45) (69): was synthesized using procedure E from 68, N-methyl 
piperazine and EDCI. A solution of 68 (430 mg, 1.61 mmol), N-Methyl piperazine (0.35 
mL, 3.22 mmol) and DMAP (6 mg, 0.05 mmol) was prepared in 12 mL anhydrous THF 
and then EDCI (615 mg, 3.22 mmol) was added. The reaction mixture was stirred at 23 
oC for 6 hrs; completion of reaction was followed by TLC. The crude product was 
isolated on SiO2 using CHCl3, 1% MeOH, 1% TEA. The fumarate salt of the compound 
was prepared from fumaric acid (186 mg, 1.61 mmol) followed by recrystallization from 
hot EtOH to give 81 mg (14%) of a white solid. MP = 155.0 – 160 oC. SiO2 TLC Rf  0.2 
(CHCl3 + 2% MeOH).  
1H NMR (400 MHz, CDCl3): δ 2.68 (s, 3 H, CH3), 2.83-2.94 (br, 
4 H, 2CH2), 3.57 (br, 4 H, 2CH2), 6.72 (s, 2 H, CH=CH), 6.82-6.86 (m, 1 H, Ar), 6.89-
6.94 (m, 1 H, Ar), 6.97-7.01 (m, 1 H, Ar), 7.04-7.12 (m, 2 H, Ar), 7.14-7.18 (m, 1 H, Ar). 
Anal Calcd for C22H22F3N3O5. 0.55 % Fumaric acid. 0.78 %  EA: C, 54.87; H, 5.13; N, 
7.02. Found: C, 54.98; H, 4.88; N, 6.86. 
 
3,4-difluoro-2-((2-fluorophenyl)amino)benzamide (SC-2-37) (70):  was synthesized 
using procedure B from 68, (267 mg, 1 mmol) and 7 N NH3 in methanol (0.65 mL, 5.03 
mmol). The crude product was isolated on SiO2 using hexane/EA to give 96 mg (36%) of 
a white powder. MP = 157.6 – 161.2 oC. 1H NMR (400 MHz, CDCl3): δ 6.82-6.88 (m, 2 
H, NH2), 6.91-6.97 (m, 1 H, Ar), 6.99-7.10 (m, 3 H, Ar), 7.44 (ddd, 1 H, J = 2.1 Hz, J = 
5.5 Hz and J = 8.8 Hz, Ar), 8.45 (s, 1 H, Ar). Anal Calcd for C13H9F3N2O: C, 58.65; H, 
3.41; N, 10.52; F, 21.41. Found: C, 58.22; H, 3.27; N, 10.20; F, 21.71. 
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2-fluoro-4-iodo-N-methylaniline (SC-2-20 amine) (108): 2-fluoro-4-iodoaniline (474 
mg, 2 mmol) was added to a dry 100 mL round bottom flask containing a suspension of 
NaOMe (540 mg, 10 mmol) in MeOH (5 mL). This mixture was poured into a suspension 
of paraformaldehyde (84 mg, 2.8 mmol) in anhydrous MeOH (4 mL) and the reaction 
mixture was stirred at 25 oC for 5 h. After 5 h, NaBH4 (75 mg, 2 mmol) was added and 
the reaction mixture was refluxed at 90 oC for 2.5 h. The solvent was evaporated and the 
reaction mixture was treated with 5 mL 1 M KOH. The product was extracted into diethyl 
ether (2 X 8 mL) and dried over Na2SO4. The extract was decanted and the solvent was 
removed under reduced pressure. The crude product was isolated on SiO2 using 20% EA/ 
hexane to provide 270 mg (54%) of white needles. MP = 44 oC. SiO2 TLC Rf  0.75 (2:1 
hexane/EA).  1H NMR (400 MHz, CDCl3): δ 2.85 (d, 3 H, J = 4.6 Hz), 3.97 (s, 1 H, NH), 
6.43 (t, 1 H, J = 8.8 Hz), 7.22-7.26 (m, 1 H, Ar), 7.30 (d, 1 H, J = 9.3 Hz, Ar). Anal 
Calcd for C7H7FIN: C, 33.39; H, 2.81; N, 5.58. Found: C, 33.69; H, 2.67; N, 5.64. 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid (SC-2-32) (76): A 
100 mL dry round bottom flask was charged with 2-fluoro-4-iodo-N-methylaniline (270 
mg, 1.07 mmol), 2,3,4-trifluorobenzoic acid, (192 mg, 1.09 mmol), and 10 mL of 
anhydrous THF. The reaction mixture was cooled with an ice-bath to 0 oC and LiNH2 (60 
mg, 2.6 mmol) was added in portions 2 portions over 5 min.  The reaction was then 
warmed to 58 oC (external temperature) and stirred for 48 h. 1 N HCl was then added to 
the reaction mixture at 0 oC to obtain a final pH of 1.0 (red to pHydrion paper). The 
reaction mixture was extracted three times with 5 mL portions of Et2O, washed three 
times with 5 mL portions of 1 N HCl, washed with NaCl (aq, sat) and dried over Na2SO4.  
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The extract was decanted and the solvent was removed under reduced pressure. The 
crude product was isolated on SiO2 using 3:1 hexane/EA and recrystallized from toluene 
and hexanes to provide 286 mg (66 %) of brown crystals. MP = 86.2 – 89.1 oC. SiO2 
TLC Rf 0.45 (2:1 hexane/EA). 
1H NMR (500 MHz, CDCl3): δ 3.34 (s, 3 H), 6.97 (t, 1 H, 
J = 8.8 Hz, Ar), 7.24-7.27 (m, 1 H, Ar), 7.35-7.37 (dd, 1 H, J = 2.0 Hz and J = 11.4 Hz, 
Ar), 7.50 (d, 1 H, J = 8.6 Hz, Ar), 8.07-8.10 (m, 1 H, Ar). Anal Calcd for C14H9F3INO2. 
0.0436 % C6H5CH3: C, 41.78; H, 2.29; N, 3.40. Found: C, 41.77; H, 2.42; N, 3.35. 
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Chapter 7 
 
Summary 
 
List of compounds prepared 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (SC-1-180).   
 
391,2,3 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-151 primary amide) 
 
571,2,3 
 
 115 
 
 
N,N-diethyl-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-65) 
 
591,2 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N,N-dimethylbenzamide (SC-1-69) 
 
581,2 
 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-methylbenzamide (SC-1-72 amide)  
 
601,2 
 
 116 
Methyl 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoate (SC-1-72 ester) 
 
621,2 
 
Tert-butyl 4-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)piperazine-1-
carboxylate (SC-1-75) 
 
641,2 
 
(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(piperazin-1-yl)methanone 
hydrochloride (SC-1-79) 
 
631,2 
 
 117 
N-ethyl-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (SC-1-80) 
 
611,2 
 
N-(2-(dimethylamino)ethyl)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-
methylbenzamide hydrochloride (SC-1-122) 
 
651,2 
 
2-((2-fluoro-4-iodophenyl)amino)benzoic acid (SC-1-14 acid) 
 
98 
 
 
 
 118 
(2-((2-fluoro-4-iodophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
hydrochloride (SC-1-24 amide) 
 
741,2 
 
2-(phenylamino)benzoic acid (SC-1-39 acid) 
 
25 
 
(4-methylpiperazin-1-yl)(2-(phenylamino)phenyl)methanone (SC-1-177 amide) 
 
751,2,3 
 
 
 
 
 119 
3,4-difluoro-2-(phenylamino)benzoic acid (SC-1-175 acid) 
 
711,2 
 
3,4-difluoro-2-(phenylamino)phenyl)(4-methylpiperazin-1-yl)methanone (SC-1-181) 
 
721,2,3 
 
3,4-difluoro-2-((2-fluorophenyl)amino)benzoic acid (SC-2-25 acid) 
 
681,2 
 
 
 
 
 120 
(3,4-difluoro-2-((2-fluorophenyl)amino)phenyl)(4-methylpiperazin-1-yl)methanone 
mono-fumarate (SC-2-45) 
 
691,2 
 
3,4-difluoro-2-((2-fluorophenyl)amino)benzamide (SC-2-37) 
 
701,2,3 
 
2-fluoro-4-iodo-N-methylaniline (SC-2-20 amine) 
 
108 
 
 
 121 
3,4-difluoro-2-((2-fluoro-4-iodophenyl)(methyl)amino)benzoic acid (SC-2-32 acid) 
 
761,2 
 
 
1: Biological testing: Cellular assay for inhibition for pERK isoforms (MEK inhibition) 
2: Biological testing: MDA-MB-231 proliferation studies and survey for EMT activity 
3: Mouse hollow fiber assay 
 
Acheivments: 
Synthesis of analogs of diphenylamines and identificaion of compounds with the best 
MEK5 selectivity and potency (compound 72). 
Idenitification of small molecule compouds that can effect the phenomenon of reversal of 
epithilial to mesenchymal transition in MDA-MB-231 triple negative breast cancer cell 
line (compound 57). 
Our collaborators are doing experiments to determine the IC50 values of the compounds 
which will give us a clear path to go forward with the animal model testing. 
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Appendix 
 
Biological evaluation 
 
MEK5 
Biological assay 
The biological testing of these compounds was conducted in the laboratory of Dr. Jane 
Cavanaugh (Duquesne University, Pittsburgh). 
 
Cell Culture and treatment 
MDA-MB-231 cells were grown on 10cm cell culture plates [Sarstedt] in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Gibco) with Ham's F12 Nutrient Mixture (1:1) 
(Invitrogen), 10% heat-inactivated FBS [Atlanta Biological and 0.5% penicillin/ 
streptomycin [Gibco]. Cells were maintained at 37°C with 5% CO2. Plating of the cells 
was done 36 hours before treatment in 35mm culture plates [Sarstedt] and allowed to 
reach confluence. To test MEK-5 inhibitors, the cells were treated with epidermal growth 
factor (EGF; Sigma-Aldrich) 30 min after treatment with the compounds. 15 min after the 
addition of EGF, the cells were washed with 1XPBS [Sigma-Aldrich] and then lysed in 
1% Triton X-100 buffer containing 20 mM Tris (pH 6.8), 137 mM NaCl, 25 mM beta 
glycerophosphate, 2 mM NaPPi, 2 mM EDTA, 1 mM Na3VO4, 10% glycerol, 5 μg/mL 
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leupeptin, 5 μg/mL aprotinin, 2 mM benzamidine, 0.5 mM DTT, and 1 mM PMSF. The 
lysates were then centrifuged at 10,000 rpm for 10 min at 4°C. 
 
Western Blot Analysis 
Total protein content was assessed by Bradford Bio-Rad protein assay (Cat. No. 500-
0006, Bio-Rad, Hercules, CA) and 30 μg of protein was loaded on a 8% SDS-PAGE gel 
for phosphorylated and total ERK1/2 and ERK5 proteins. After running the samples, gels 
were transferred to a nitrocellulose membrane (Cat. No. 926-31092, Licor Biosciences, 
Lincoln, NE). After transfer, membranes were washed for 5 min with 1X PBS and 
blocked for 1 h in a Casein Blocking Buffer (Cat. No. 927-40200, Licor Biosciences) at 
room temperature. Membranes were then incubated overnight at 4 ºC in primary antibody 
in CBB with 0.2% Tween-20. Antibodies included rabbit anti-phospho-ERK1/2 (Dilution 
– 1:1000, Cat. No. 9101, Cell Signaling, Beverly, MA), mouse anti-total ERK1/2 
(Dilution – 1:1000, Cat. No. 9107, Cell Signaling), and rabbit anti-total ERK5 (Dilution – 
1:1,000, Cat. No. 3372, Cell Signaling). Mouse anti-α-Tubulin (Dilution – 1:10,000, Cat. 
No. T5168, Sigma–Aldrich) was used as a loading control. After incubation with primary 
antibody, blots were washed in 1X PBS solution with 0.2% Tween-20 (1X PBS-T) and 
incubated with goat anti-rabbit (Dilution – 1:  10,000, Cat. No. 926-68021, LICOR 
Biosciences) and goat anti-mouse (Dilution – 1:  10,000, Cat. No. 926-32210, LICOR 
Biosciences) secondary antibodies for 1 h at room temperature. After washing the 
membranes with 1X PBS-T, the protein bands were visualized on an Odyssey Infrared 
Imager and quantified with Odyssey software (LICOR Biosciences). 
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Compounds 
pERK-5 
relative activity 
(%)   
pERK-5 decrease 
(%)  
pERK-1/2 
relative activity 
(%)   
pERK-1/2 decrease 
(%)  
DMSO 100 0 100 0 
SC-1-75 -- 8.4 -- 70.9 
SC-1-65 7.4 -- -- 5.5 
SC-1-24 -- 30.9 -- 33.5 
SC-1-122 -- 9.4 -- 27.9 
SC-1-69 -- 0.2 -- 87.3 
SC-1-72 amide -- 20.4 -- 99.6 
SC-1-72 ester -- 13.0 -- 98.9 
SC-1-79 6.2 -- -- 99.0 
SC-1-80 -- 8.5 -- 98.6 
SC-1-177 -- 71 -- 29.3 
SC-1-181 -- 82.4 8.5 -- 
SC-1-151 -- 59 -- 96.8 
SC-1-180 -- 20.1 -- 98.5 
SC-1-175 -- 10.4 -- 7.1 
SC-2-25 -- 11.1 7.1 -- 
SC-2-32 5.5 -- -- 33.5 
SC-2-37 -- 56.1 -- 52.8 
SC-2-45 -- 40.5 -- 16.5 
U0126 -- 43 -- 99.6 
 137 
XMD8-92 -- 95.2 -- 50.1 
PD 0325901 -- 95.9 -- 99.7 
 
Table 13: MEK1/2 and MEK inhibition data 
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Figure 41: MEK1/2 and MEK5 inhibition graphs. 
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Biological data from Dr. Matthew Burow 
The biological testing of the compounds was conducted in the laboratory of Dr. Matthew 
Burow (Tulane University, New Orleans, LA). 
Crystal violet proliferation assay Protocol: 
MDA-MB 231 cells were used as they express the triple negative cancer phenotype. 
1) MDA-MB-231 were seeded in 96-well plates at a density of 2,000 cells per well 
in 5% charcoal-stripped phenol free DMEM, allowed to attach overnight, and 
subsequently treated with DMSO and MEK inhibitor compounds. 
2) Plates were harvested on days 3, 5 and 7, fixed with glutaraldehyde and stained 
with Crystal Violet. Cells were observed for morphological changes under an 
inverted microscope. 
3) The cells were washed, lysed, and the absorbance of Crystal Violet sequestered in 
living cells was determined at 630 nM in a Biotek Synergy plate reader. 
4) Wells were conducted in duplicate. Experiments were run in triplicate. 
5) Cells were normalized to initial cell count. 
 
Biological data 
 
Figure 42: Dose-response effect of compound 57 (SC-1-151) at different concentrations. 
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Figure 43: MDA-MB-231 – SC-1-151 treatment (Dual MEK1/2 and MEK5 inhibitor) – 
Morphology at day 3. 
 
 
Figure 44: MDA-MB-231 – SC-1-151 treatment (Dual MEK1/2 and MEK5 inhibitor) – 
Morphology at day 14. 
 
DMSO 0.001 µM 
0.01 µM 0.1 µM 
1.0 µM 10 µM 
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Figure 45: Fold change of E-Cadherin upon administration of 57 (SC-1-151). 
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Construction of the homology model: 
• Of the three human isoforms; A, B and C, a model of the B isoform (b) (Q13163) 
was built following CLUSTAL W225-26 sequence alignment. 
• 3EQC (MEK1)27 was used as the 3-D structural template and the low resolution 
residues in the template were modeled prior to model building.  
• The constitutively active mutant of human MEK5 β [MEK5 β DD] was modeled 
by mutating Ser 311 and Thr 315 to Asp. 
• Care was taken to ensure that the DFG and HRD motifs were aligned properly 
with the template. 
 
Figure 46: Sequence Alignment of Human MEK5 β DD with Human MEK1.  
Conserved residues are highlighted in blue, similar residues are highlighted in magenta.  
Helices represented by coils, beta-strand by blue arrow and loops by black lines. 
Domains, HRD and DFG aligned were highlighted by vertical boxes.  (The homology 
model analysis was conducted by Dr. Sankar Manepalli in Madura lab and is currently 
being prepared as a manuscript for submission in September 2014). 
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Entry Entry name Protein names 
Gene 
names Length 
Q02750 MP2K1_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 1 (MAP kinase 
kinase 1) (MAPKK 1) (MKK1) (EC 
2.7.12.2) (ERK activator kinase 1) 
(MAPK/ERK kinase 1) (MEK 1) 
MAP2K1 
MEK1 
PRKMK1 393 
P36507 MP2K2_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 2 (MAP kinase 
kinase 2) (MAPKK 2) (EC 2.7.12.2) 
(ERK activator kinase 2) (MAPK/ERK 
kinase 2) (MEK 2) 
MAP2K2 
MEK2 
MKK2 
PRKMK2 400 
P46734 MP2K3_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 3 (MAP kinase 
kinase 3) (MAPKK 3) (EC 2.7.12.2) 
(MAPK/ERK kinase 3) (MEK 3) 
(Stress-activated protein kinase 
kinase 2) (SAPK kinase 2) (SAPKK-2) 
(SAPKK2) 
MAP2K3 
MEK3 
MKK3 
PRKMK3 
SKK2 347 
P45985 MP2K4_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 4 (MAP kinase 
kinase 4) (MAPKK 4) (EC 2.7.12.2) 
(JNK-activating kinase 1) 
(MAPK/ERK kinase 4) (MEK 4) 
(SAPK/ERK kinase 1) (SEK1) (Stress-
activated protein kinase kinase 1) 
(SAPK kinase 1) (SAPKK-1) (SAPKK1) 
(c-Jun N-terminal kinase kinase 1) 
(JNKK) 
MAP2K4 
JNKK1 
MEK4 
MKK4 
PRKMK4 
SEK1 
SERK1 
SKK1 399 
Q13163 MP2K5_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 5 (MAP kinase 
kinase 5) (MAPKK 5) (EC 2.7.12.2) 
(MAPK/ERK kinase 5) (MEK 5) 
MAP2K5 
MEK5 
MKK5 
PRKMK5 448 
P52564 MP2K6_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 6 (MAP kinase 
kinase 6) (MAPKK 6) (EC 2.7.12.2) 
(MAPK/ERK kinase 6) (MEK 6) 
(Stress-activated protein kinase 
kinase 3) (SAPK kinase 3) (SAPKK-3) 
(SAPKK3) 
MAP2K6 
MEK6 
MKK6 
PRKMK6 
SKK3 334 
O14733 MP2K7_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 7 (MAP kinase 
kinase 7) (MAPKK 7) (EC 2.7.12.2) 
(JNK-activating kinase 2) 
(MAPK/ERK kinase 7) (MEK 7) 
(Stress-activated protein kinase 
kinase 4) (SAPK kinase 4) (SAPKK-4) 
MAP2K7 
JNKK2 
MEK7 
MKK7 
PRKMK7 
SKK4 419 
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(SAPKK4) (c-Jun N-terminal kinase 
kinase 2) (JNK kinase 2) (JNKK 2) 
 
FASTA SEQUENCES: 
>sp|Q02750|MP2K1_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 1 OS=Homo sapiens GN=MAP2K1 PE=1 SV=2 
MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKV 
GELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHE 
CNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYL 
REKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHY 
SVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSY 
GMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAF 
IKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV 
 
>sp|P36507|MP2K2_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 2 OS=Homo sapiens GN=MAP2K2 PE=1 SV=1 
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ 
KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ 
VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG 
LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ 
GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP 
PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL 
KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV 
 
>sp|P46734|MP2K3_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 3 OS=Homo sapiens GN=MAP2K3 PE=1 SV=2 
MESPASSQPASMPQSKGKSKRKKDLRISCMSKPPAPNPTPPRNLDSRTFITIGDRNFEVE 
ADDLVTISELGRGAYGVVEKVRHAQSGTIMAVKRIRATVNSQEQKRLLMDLDINMRTVDC 
FYTVTFYGALFREGDVWICMELMDTSLDKFYRKVLDKNMTIPEDILGEIAVSIVRALEHL 
HSKLSVIHRDVKPSNVLINKEGHVKMCDFGISGYLVDSVAKTMDAGCKPYMAPERINPEL 
NQKGYNVKSDVWSLGITMIEMAILRFPYESWGTPFQQLKQVVEEPSPQLPADRFSPEFVD 
FTAQCLRKNPAERMSYLELMEHPFFTLHKTKKTDIAAFVKEILGEDS 
 
>sp|P45985|MP2K4_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 4 OS=Homo sapiens GN=MAP2K4 PE=1 SV=1 
MAAPSPSGGGGSGGGSGSGTPGPVGSPAPGHPAVSSMQGKRKALKLNFANPPFKSTARFT 
LNPNPTGVQNPHIERLRTHSIESSGKLKISPEQHWDFTAEDLKDLGEIGRGAYGSVNKMV 
HKPSGQIMAVKRIRSTVDEKEQKQLLMDLDVVMRSSDCPYIVQFYGALFREGDCWICMEL 
MSTSFDKFYKYVYSVLDDVIPEEILGKITLATVKALNHLKENLKIIHRDIKPSNILLDRS 
GNIKLCDFGISGQLVDSIAKTRDAGCRPYMAPERIDPSASRQGYDVRSDVWSLGITLYEL 
ATGRFPYPKWNSVFDQLTQVVKGDPPQLSNSEEREFSPSFINFVNLCLTKDESKRPKYKE 
LLKHPFILMYEERAVEVACYVCKILDQMPATPSSPMYVD 
 
>sp|Q13163|MP2K5_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 5 OS=Homo sapiens GN=MAP2K5 PE=1 SV=2 
MLWLALGPFPAMENQVLVIRIKIPNSGAVDWTVHSGPQLLFRDVLDVIGQVLPEATTTAF 
EYEDEDGDRITVRSDEEMKAMLSYYYSTVMEQQVNGQLIEPLQIFPRACKPPGERNIHGL 
KVNTRAGPSQHSSPAVSDSLPSNSLKKSSAELKKILANGQMNEQDIRYRDTLGHGNGGTV 
YKAYHVPSGKILAVKVILLDITLELQKQIMSELEILYKCDSSYIIGFYGAFFVENRISIC 
TEFMDGGSLDVYRKMPEHVLGRIAVAVVKGLTYLWSLKILHRDVKPSNMLVNTRGQVKLC 
DFGVSTQLVNSIAKTYVGTNAYMAPERISGEQYGIHSDVWSLGISFMELALGRFPYPQIQ 
KNQGSLMPLQLLQCIVDEDSPVLPVGEFSEPFVHFITQCMRKQPKERPAPEELMGHPFIV 
QFNDGNAAVVSMWVCRALEERRSQQGPP 
 
>sp|P52564|MP2K6_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 6 OS=Homo sapiens GN=MAP2K6 PE=1 SV=1 
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MSQSKGKKRNPGLKIPKEAFEQPQTSSTPPRDLDSKACISIGNQNFEVKADDLEPIMELG 
RGAYGVVEKMRHVPSGQIMAVKRIRATVNSQEQKRLLMDLDISMRTVDCPFTVTFYGALF 
REGDVWICMELMDTSLDKFYKQVIDKGQTIPEDILGKIAVSIVKALEHLHSKLSVIHRDV 
KPSNVLINALGQVKMCDFGISGYLVDSVAKTIDAGCKPYMAPERINPELNQKGYSVKSDI 
WSLGITMIELAILRFPYDSWGTPFQQLKQVVEEPSPQLPADKFSAEFVDFTSQCLKKNSK 
ERPTYPELMQHPFFTLHESKGTDVASFVKLILGD 
 
>sp|O14733|MP2K7_HUMAN Dual specificity mitogen-activated protein 
kinase kinase 7 OS=Homo sapiens GN=MAP2K7 PE=1 SV=2 
MAASSLEQKLSRLEAKLKQENREARRRIDLNLDISPQRPRPTLQLPLANDGGSRSPSSES 
SPQHPTPPARPRHMLGLPSTLFTPRSMESIEIDQKLQEIMKQTGYLTIGGQRYQAEINDL 
ENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIV 
QCFGTFITNTDVFIAMELMGTCAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVI 
HRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYD 
IRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDC 
LTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFR 
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MEK Isozymes: (Last update 7/9/2014) 
 
 
MEK1: 
Common 
abbreviation 
MEK1 
Previous and 
unofficial 
names 
MEK1,  MAPKK1,  MKK1,  PRKMK1,  Mek1,  ERK activator kinase 
1,  MAP kinase kinase 1,  MAP kinase/Erk kinase 1,  MAPK/ERK 
kinase 1,  MAPKK 1,  dual specificity mitogen-activated protein kinase 
kinase 1,  Prkmk1  
  
Genes MAP2K1 (Hs), Map2k1 (Mm), Map2k1 (Rn) 
  
Ensembl ID 
ENSG00000169032 (Hs), ENSMUSG00000004936 (Mm), 
ENSRNOG00000010176 (Rn)  
UniProtKB  Q02750 (Hs), P31938 (Mm), Q01986 (Rn)  
EC number 2.7.12.2  
 
Post-translational modifications: 
Residue Modification 
1   N-acetylmethionine   
222   O-acetylserine   
222  Phosphoserine   
226  O-acetylserine 
226  Phosphoserine 
293  Phosphoserine  
295  Phosphoserine  
394  Phosphothreonine  
396  Phosphothreonine 
 
Nucleotide binding site:  
74-82 
 
 
MEK2: 
Common 
abbreviation 
MEK2 
Previous and 
unofficial names 
PRKMK2,  MEK2,  MKK2,  Prkmk2,  ERK activator kinase 2,  MAP 
kinase kinase 2,  MAPK/ERK kinase 2,  MAPKK 2,  MEK 2,  dual 
specificity mitogen-activated protein kinase kinase 2,  MAP kinase/Erk 
kinase  
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Genes MAP2K2 (Hs), Map2k2 (Mm), Map2k2 (Rn) 
  
Ensembl ID 
ENSG00000126934 (Hs), ENSMUSG00000035027 (Mm), 
ENSRNOG00000020005 (Rn)  
UniProtKB  P36507 (Hs), Q63932 (Mm), P36506 (Rn)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
1  N-acetylmethionine   
222  O-acetylserine 
222  Phosphoserine 
226  O-acetylserine;  
226  Phosphoserine 
293  Phosphoserine  
295  Phosphoserine  
394  Phosphothreonine 
396  Phosphothreonine 
 
Nucleotide binding site:  
78-86 
 
 
MEK3: 
Common 
abbreviation 
MKK3 
Previous and 
unofficial names 
PRKMK3,  MAPK/ERK kinase 3,  MAP kinase kinase 3,  dual 
specificity mitogen activated protein kinase kinase 3,  MEK3,  MKK3,  
MAPKK3,  LOC303200,  Map2k3_predicted,  Prkmk3  
  
Genes MAP2K3 (Hs), Map2k3 (Mm), Map2k3 (Rn) 
  
Ensembl ID 
ENSG00000034152 (Hs), ENSMUSG00000018932 (Mm), 
ENSRNOG00000006612 (Rn)  
UniProtKB  P46734 (Hs), O09110 (Mm)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
1  N-acetylmethionine  
3  Phosphoserine  
15  Phosphoserine  
218  Phosphoserine  [S → E: Constitutive activation] 
222  Phosphothreonine  [T → E: Constitutive activation] 
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Splice variants: 
Isoform 1: [VSP_004878] 
Residues 1-29 missing: MESPASSQPA SMPQSKGKSK RKKDLRISC 
Isoform 2: [VSP_004877] 
 Residues 1-16 altered:  MGVQGTLMSR DSQTPHLLSI LGKS 
 
Isoform 3: (canonical form)  
 
Nucleotide binding site:  
70-78 
 
 
MEK4: 
Common 
abbreviation 
MKK4 
Previous and 
unofficial 
names 
SERK1,  MEK4,  JNKK1,  PRKMK4,  MKK4,  LOC287398,  Map2k4_predicted,  Sek1,   
SAPK/ERK kinase 1,  dual specificity mitogen-activated protein kinase kinase 4,   
mitogen activated protein kinase kinase 4,  Serk1  
  
Genes MAP2K4 (Hs), Map2k4 (Mm), Map2k4 (Rn) 
  
Ensembl ID ENSG00000065559 (Hs), ENSMUSG00000033352 (Mm), ENSRNOG00000003834 (Rn)  
UniProtKB  P45985 (Hs), P47809 (Mm)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
2  N-acetylalanine  
90  Phosphoserine  
257  Phosphoserine [by MAP3K] 
261  Phosphothreonine [by MAP3K] 
 
Splice variants: 
Isoform 1: (canonical form)  
 
Isoform 2: [VSP_038838] 
 Residue 39 altered: G → GFQINFCEKAQS 
 
Nucleotide binding site:  
108-116 
 
 
 
 149 
MEK5: 
Common 
abbreviation 
MEK5 
Previous and 
unofficial names 
PRKMK5,  MEK5,  MAPKK5,  HsT17454,  Mek5,  MAP kinase 
kinase 5,  MAPK/ERK kinase 5,  MAPKK 5,  MEK 5,  dual specificity 
mitogen-activated protein kinase kinase 5  
  
Genes MAP2K5 (Hs), Map2k5 (Mm), Map2k5 (Rn) 
  
Ensembl ID 
ENSG00000137764 (Hs), ENSMUSG00000058444 (Mm), 
ENSRNOG00000007926 (Rn)  
UniProtKB  Q13163 (Hs), Q9WVS7 (Mm), Q62862 (Rn)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
311  Phosphoserine 
315  Phosphothreonine 
 
Splice variants: 
Isoform A:  
     349-358: Missing. 
 
Isoform B: (canonical form) 
 
Isoform C: (partial sequence) 
    349-358: Missing. 
     444-448: QQGPP → LASLPSPSPSV 
 
Isoform 4: [VSP_043333] (inferred from mRNA, protein not isoated) 
 Alternate sequence 1-45: MLWLALGPFP AMENQVLVIR IKIPNSGAVD  
WTVHSGPQLL FRDVL → MMEGHFPQS 
 
Nucleotide binding site:  
172-180 
 
 
MEK6: 
Common 
abbreviation 
MKK6 
Previous and 
unofficial 
names 
PRKMK6,  MAPKK 6,  MEK6,  protein kinase mitogen-activated kinase 
6,  MAP kinase kinase 6,  MGC93287,  Mkk6,  dual specificity mitogen-
activated protein kinase kinase 6,  MKK6,  SAPKK3,  Prkmk6,  Stress-
activated protein kinase kinase 3,  SAPK kinase 3,  SKK3  
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Genes MAP2K6 (Hs), Map2k6 (Mm), Map2k6 (Rn) 
  
Ensembl ID 
ENSG00000108984 (Hs), ENSMUSG00000020623 (Mm), 
ENSRNOG00000004437 (Rn)  
UniProtKB  P52564 (Hs), P70236 (Mm), Q925D6 (Rn)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
311  Phosphoserine 
315  Phosphothreonine 
 
Splice variants: 
Isoform 1: (canonical form) [MKK6b] 
 
Isoform 2: [MKK6] 
 Missing residues 1-56: [VSP_004882] 
 
Nucleotide binding site:  
59-67 
 
 
MEK7: 
Common 
abbreviation 
MKK7 
Previous and 
unofficial 
names 
PRKMK7,  MKK7,  Jnkk2,  JNKK2,  JNK kinase 2,  Stress-activated 
protein kinase kinase 4,  SAPKK4,  SKK4,  JNK-activating kinase 2,  
MAP kinase kinase 7,  MAPK/ERK kinase 7,  MAPKK 7,  MEK 7,  c-
Jun N-terminal kinase kinase 2,  dual specificity mitogen-activated 
protein kinase kinase 7,  sek2,  Prkmk7  
  
Genes MAP2K7 (Hs), Map2k7 (Mm), Map2k7 (Rn) 
  
Ensembl ID 
ENSG00000076984 (Hs), ENSMUSG00000002948 (Mm), 
ENSRNOG00000001047 (Rn)  
UniProtKB  O14733 (Hs), Q8CE90 (Mm), Q4KSH7 (Rn)  
EC number 2.7.12.2 
 
Post-translational modifications: 
Residue Modification: 
311  Phosphoserine 
315  Phosphothreonine 
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Splice variants: 
Isoform 1: (canonical form) [Isoform A,] 
 
Isoform 2: [Isoform B] [VSP_004883] 
 Insertion at 111: T → IIVITLSPAPAPSQRAA  
 
Isoform 3: (1) [VSP_022309] 
 Insertion at 42: T → IIVITLSPAPAPSQRAA [VSP_022309] 
 
Isoform 4: [VSP_022310] (extrapolation from cDNA library) 
 Insertion at 312-312: L → LPCPSPSQ 
 
Nucleotide binding site: 
122-134  
 
 
Analysis of isoform homology at the ATP site: 
 
MEK 1:     LGAGNGGVV 
MEK 2:     LGAGNGGVV 
MEK 3:     LGRGAYGVV 
MEK 4:     IGRGAYGSV 
MEK 5:     LGHGNGGTV  
MEK 6:     LGRGAYGVV 
MEK 7: LGEMMGSGTCGQV 
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Domain analysis: 
Lower platform near triphosphate: 
140- 147: HRDVKPSNM (MEK5DD) 
MEK5DD with amide docked.  The HRDVKPSNM sequence is displayed. 
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CLUSTAL analysis of the HRDVKPSNM  sequence; for all 7 MEK’s: 78-88 % 
homology: 
SP|sp|Q13163|MP2K5_HUMAN|MP2K5 HRDVKPSNM 
                               ||||||||. 
SP|sp|Q02750|MP2K1_HUMAN|MP2K1 HRDVKPSNI 
 
Percentage ID = 88.89 
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C-helix: 
163-175: VSTQLVNSIAKTY 
 
 
 
 
CLUSTAL analysis of the VSTQLVNSIAKTY sequence; for all 7 MEK’s: 46-77 % 
homology: 
SP|sp|Q13163|MP2K5_HUMAN|MP2K5 VSTQLVNSIAKTY 
                               || ||..|.|... 
SP|sp|Q02750|MP2K1_HUMAN|MP2K1 VSGQLIDSMANSF 
 
Percentage ID = 46.15 
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Back to C-helix: 159-162: CDFG 
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CLUSTAL analysis of the CDFG sequence; for all 7 MEK’s: 100 % homology: 
 
 
Hinge and -sheet: 
35-37: NGG   54-56: KVI   98-100: ICT 
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CLUSTAL analysis of the Hinge: 35-37: NGG; for all 7 MEK’s: 25-100 % homology: 
CLUSTAL analysis of the -sheet: 54-56: KVI; for all 7 MEK’s: 46-77 % homology: 
CLUSTAL analysis of the -sheet: 98-100: ICT; for all 7 MEK’s: 50-67 % homology: 
 
Hinge and -sheet: 
35-37: NGG   54-56: KVI   98-100: ICT 
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Homology tree for MEK isoforms: 
 
 
 
 
 
Overall Homology: 
MEK5 with MEK1: 38 % 
MEK5 with MEK2: 37 % 
MEK5 with MEK3: 39 % 
MEK5 with MEK4: 35 % 
MEK5 with MEK6: 40 % 
MEK5 with MEK7: 30 % 
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Swiss-Prot references: 
MEK1 
Entry name MP2K1_HUMAN 
Accession Primary (citable) accession number: Q02750 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  July 1, 1993 
Last sequence update:    January 23, 2007 
Last modified:     July 9, 2014 
 
 
MEK2 
Entry name MP2K2_HUMAN 
Accession Primary (citable) accession number: P36507 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  June 1, 1994 
Last sequence update:    June 1, 1994 
Last modified:     July 9, 2014 
 
 
MEK3 
Entry name MP2K3_HUMAN 
Accession Primary (citable) accession number: P46734 
Secondary accession number(s): B3KSK7 expand/collapse secondary AC list Q9UE72 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  November 1, 1995 
Last sequence update:    November 1, 2002 
Last modified:     July 9, 2014 
 
MEK4 
Entry name MP2K4_HUMAN 
Accession Primary (citable) accession number: P45985 
Secondary accession number(s): B2R7N7 expand/collapse secondary AC list Q6PIE6 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  November 1, 1995 
Last sequence update:    November 1, 1995 
Last modified:     July 9, 2014 
 
MEK5 
Entry name MP2K5_HUMAN 
Accession Primary (citable) accession number: Q13163 
Secondary accession number(s): B4DE43, Q92961, Q92962 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  November 1, 1997 
Last sequence update:    November 28, 2006 
Last modified:     July 9, 2014 
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MEK6 
Entry name MP2K6_HUMAN 
Accession Primary (citable) accession number: P52564 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  October 1, 1996 
Last sequence update:    October 1, 1996 
Last modified:     July 9, 2014 
 
MEK7 
Entry name MP2K7_HUMAN 
Accession Primary (citable) accession number: O14733 
Secondary accession number(s): B2R9S5 expand/collapse secondary AC list Q8IY10 
Entry history  
Integrated into UniProtKB/Swiss-Prot:  May 30, 2000 
Last sequence update:    May 30, 2000 
Last modified:     July 9, 2014 
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